17,889 results on '"DUCTAL carcinoma"'
Search Results
2. Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
- Author
-
Amgen
- Published
- 2024
3. Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome.
- Author
-
Strand, Siri H., Houlahan, Kathleen E., Branch, Vernal, Lynch, Thomas, Rivero-Guitiérrez, Belén, Harmon, Bryan, Couch, Fergus, Gallagher, Kristalyn, Kilgore, Mark, Wei, Shi, DeMichele, Angela, King, Tari, McAuliffe, Priscilla, Curtis, Christina, Owzar, Kouros, Marks, Jeffrey R., Colditz, Graham A., Hwang, E. Shelley, and West, Robert B.
- Subjects
RACE ,DUCTAL carcinoma ,CARCINOMA in situ ,WHITE women ,GENE expression ,CANCER invasiveness - Abstract
Background: Ductal carcinoma in situ (DCIS) is a non-obligate precursor to invasive breast cancer (IBC). Studies have indicated differences in DCIS outcome based on race or ethnicity, but molecular differences have not been investigated. Methods: We examined the molecular profile of DCIS by self-reported race (SRR) and outcome groups in Black (n = 99) and White (n = 191) women in a large DCIS case-control cohort study with longitudinal follow up. Results: Gene expression and pathway analyses suggested that different genes and pathways are involved in diagnosis and ipsilateral breast outcome (DCIS or IBC) after DCIS treatment in White versus Black women. We identified differences in ER and HER2 expression, tumor microenvironment composition, and copy number variations by SRR and outcome groups. Conclusions: Our results suggest that different molecular mechanisms drive initiation and subsequent ipsilateral breast events in Black versus White women. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.
- Author
-
Wong, Clarissa Jing Wen, Md Nasir, Nur Diyana, Koh, Valerie Cui Yun, Campbell, Fiona, Fox, Stephen, Lakhani, Sunil R, Myles, Nickolas, Yip, George, Colling, Richard, Cree, Ian A, Lokuhetty, Dilani, and Tan, Puay Hoon
- Subjects
- *
CARCINOMA in situ , *DUCTAL carcinoma , *MOLECULAR pathology , *ETIOLOGY of diseases , *SCIENTIFIC observation , *BREAST - Abstract
Aims: Ductal carcinoma in situ (DCIS) is recognised by the World Health Organisation (WHO) Classification of Tumours (WCT) as a non‐invasive neoplastic epithelial proliferation confined to the mammary ducts and lobules. This report categorises the references cited in the DCIS chapter of the 5th edition of the WCT (Breast Tumours) according to prevailing evidence levels for evidence‐based medicine and the Hierarchy of Evidence for Tumour Pathology (HETP), identifying potential gaps that can inform subsequent editions of the WCT for this tumour. Methods and results: We included all citations from the DCIS chapter of the WCT (Breast Tumours, 5th edition). Each citation was appraised according to its study design and evidence level. We developed our map of cited evidence, which is a graphical matrix of tumour type (column) and tumour descriptors (rows). Spheres were used to represent the evidence, with size and colour corresponding to their number and evidence level respectively. Thirty‐six publications were retrieved. The cited literature in the DCIS chapter comprised mainly case series and were regarded as low‐level. We found an unequal distribution of citations among tumour descriptors. 'Pathogenesis' and 'prognosis and prediction' contained the most references, while 'clinical features', 'aetiology' and 'diagnostic molecular pathology' had only a single citation each. 'Prognosis and prediction' had the greatest proportion of moderate‐ and high‐levels of evidence. Conclusion: Our findings align with the disposition for observational studies inherent in the field of pathology. Our map is a springboard for future efforts in mapping all available evidence on DCIS, potentially augmenting the editorial process and future editions of WCTs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple‐negative breast cancers.
- Author
-
Batra, Harsh, Bose, Priya S C, Ding, Yang, Dai, Alan, Chen, Hui, Albarracin, Constance T, Sun, Hongxia, Sahin, Aysegul A, Yang, Fei, Wistuba, Ignacio I, and Raso, Maria G
- Subjects
- *
ADENOID cystic carcinoma , *PROTEIN overexpression , *BREAST tumors , *DUCTAL carcinoma , *BREAST cancer , *BREAST - Abstract
Background: Adenoid cystic carcinoma is a rare subtype of triple‐negative breast carcinoma. These low‐grade tumours, which are treated by simple mastectomy and have an excellent prognosis compared to other triple‐negative breast carcinomas. Solid‐variant adenoid cystic carcinomas have basaloid features and are difficult to distinguish morphologically from other triple‐negative breast cancers. Breast adenoid cystic carcinoma exhibits MYB protein overexpression, which can be detected by immunohistochemistry (IHC). Aim: We compared the IHC expression of MYB in solid‐variant adenoid cystic carcinoma with that in other triple‐negative breast cancers. Methods: We conducted IHC staining of 210 samples of triple‐negative breast cancers, including solid‐variant adenoid cystic carcinoma (n = 17), metaplastic breast carcinoma (n = 44), basaloid triple‐negative breast cancer (n = 21), and other triple‐negative invasive ductal carcinoma (n = 128). We classified nuclear staining of MYB as diffuse/strong (3+), focal moderate (2+), focal weak (1+), or none (0). Results: All 17 solid/basaloid adenoid cystic carcinoma cases exhibited 3+ MYB expression. Of the 21 solid/basaloid triple‐negative breast cancers, one (5%) had 2+ expression, seven (33%) 1+ expression, and 13 (62%) 0 expression. Of the 44 metaplastic carcinoma cases, 39 cases (89%) had no (0) staining, and the other five cases had focal weak (1+) or moderate (2+) staining. Among the 128 triple‐negative invasive ductal carcinoma cases, 92 cases (72%) had no (0) staining, 36 cases (28%) exhibited focal weak (1+) or moderate (2+) staining. Conclusions: Our study revealed diffuse/strong MYB staining (3+) only in solid/basaloid adenoid cystic carcinomas. Thus, we recommend routine MYB IHC staining in triple‐negative breast carcinoma with solid/basaloid morphology to improve diagnostic accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Nonneoplastic and neoplastic sclerosing lesions of the breast.
- Author
-
Turashvili, Gulisa
- Subjects
- *
CARCINOMA in situ , *SYMPTOMS , *DUCTAL carcinoma , *ADENOMA , *PAPILLOMA , *BREAST - Abstract
Sclerosing lesions of the breast encompass a spectrum of benign and malignant entities and often pose a diagnostic challenge. Awareness of key morphologic features and pitfalls in the assessment of morphology and immunophenotype is essential to avoid over‐ or underdiagnosis and ensure optimal clinical management. This review summarizes nonneoplastic sclerosing lesions such as radial scar/complex sclerosing lesion, sclerosing adenosis, sclerosing intraductal papilloma, sclerosing variants of ductal adenoma and nipple adenoma, and fibroadenoma with extensive sclerosis, including their clinical presentation, characteristic morphology, differential diagnostic considerations, appropriate immunohistochemical work‐up, when needed, and the clinical significance. In addition, atypical or neoplastic entities (such as atypical ductal hyperplasia, ductal carcinoma in situ, low‐grade adenosquamous carcinoma, and fibromatosis‐like metaplastic carcinoma) that can involve these sclerosing lesions are also briefly discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Radial sclerosing lesions found on core needle biopsy: excision can be safely avoided.
- Author
-
Grabenstetter, Anne, Brennan, Sandra B, Jochelson, Maxine S, Brogi, Edi, Morrow, Monica, Tan, Lee K, and D'Alfonso, Timothy M
- Subjects
- *
CORE needle biopsy , *LOBULAR carcinoma , *CARCINOMA in situ , *DUCTAL carcinoma , *SURGICAL excision , *BREAST - Abstract
Aims: Radial sclerosing lesions (RSLs) are benign breast lesions composed of glandular and epithelial proliferations with stellate architecture and fibro‐elastotic stroma, which can mimic invasive carcinoma on imaging. Surgical management following a core biopsy diagnosis of RSLs remains controversial. Methods and results: We retrospectively identified core biopsies with RSLs without atypia who underwent subsequent surgical excision between 2015 and 2021. All core biopsy slides were reviewed to confirm the diagnosis. Imaging was reviewed to determine radiological–pathological concordance. An upgrade was defined as invasive carcinoma or ductal carcinoma in situ (DCIS) in the excision. The final cohort consisted of 130 core biopsies from 124 women (median age = 52 years, range = 27–76). The imaging modality was mammogram in 52 (40%) cases, MRI in 52 (40%) and ultrasound in 26 (20%). One hundred and seven (82%) core biopsies were vacuum‐assisted and 23 (18%) were ultrasound‐guided without vacuum assistance. The median lesion size on imaging was 9 mm (range = 2–41). Overall, two (1%) cases were upgraded at excision, including one microinvasive lobular carcinoma and one 2 mm focus of invasive mammary carcinoma with associated DCIS. In both cases, the upgraded foci of carcinoma were not closely associated with the biopsy site and were considered incidental upgrades. Conclusions: This study adds to the body of literature supporting observation, rather than routine excision of radial sclerosing lesions without atypia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Effect of surgical approach on early return to intended oncologic therapy after resection for pancreatic ductal adenocarcinoma.
- Author
-
Lu, Pamela W., Lyu, Heather G., Prakash, Laura R., Chiang, Yi-Ju Sabrina, Maxwell, Jessica E., Snyder, Rebecca A., Kim, Michael P., Tzeng, Ching-Wei D., Katz, Matthew H. G., and Ikoma, Naruhiko
- Subjects
- *
SURGICAL robots , *STATISTICAL models , *EARLY medical intervention , *PATIENT safety , *PROBABILITY theory , *FISHER exact test , *KRUSKAL-Wallis Test , *PATIENT readmissions , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *MULTIVARIATE analysis , *PANCREATIC tumors , *LONGITUDINAL method , *PANCREATICODUODENECTOMY , *ADJUVANT chemotherapy , *ODDS ratio , *PANCREATECTOMY , *DUCTAL carcinoma , *CONFIDENCE intervals , *TREATMENT delay (Medicine) , *DATA analysis software , *LENGTH of stay in hospitals , *TIME - Abstract
Background: Although robotic pancreatectomy may facilitate an earlier functional recovery, the impact of a robotic pancreatectomy program during its early experience on the timing of return to intended oncologic therapy (RIOT) after surgery is unknown. Methods: In this retrospective cohort study, we used propensity score matching with a 1:2 ratio to compare patients who underwent robotic or open surgery (distal pancreatectomy or pancreatoduodenectomy) for pancreatic ductal adenocarcinoma (PDAC) during the first 3 years of our robotic pancreatectomy experience (January 2018–December 2021). Generalized estimating equations modeling was used to evaluate the effect of surgical approach on early RIOT, defined as adjuvant chemotherapy initiation within 8 weeks after surgery, and late RIOT, defined as initiation within 12 weeks after surgery. Results: The matched cohort included 26 patients who underwent robotic pancreatectomy and 52 patients who underwent open pancreatectomy. Rates of receipt of adjuvant chemotherapy were 96.2% and 78.9%, respectively. Rate of early RIOT in the robotic group (73.1% was higher than that in the open group (44.2%; P = 0.018). In multivariable analysis, a robotic approach was associated with early RIOT (odds ratio, 3.54; 95% confidence interval 1.08–11.62; P = 0.038). Surgical approach did not impact late RIOT (odds ratio, 3.21; 95% confidence interval 0.71–14.38; P = 0.128). Conclusions: Compared with open pancreatectomy, robotic pancreatectomy did not delay RIOT. In fact, odds of early RIOT were increased, which supports the oncological safety of our robotic pancreatectomy program during its implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Neoplastic Progression in Neuroendocrine Neoplasms of the Pancreas.
- Author
-
Luchini, Claudio and Scarpa, Aldo
- Subjects
- *
ADENOCARCINOMA , *TUMOR grading , *PANCREATIC tumors , *IMMUNOHISTOCHEMISTRY , *NEUROENDOCRINE tumors , *DUCTAL carcinoma , *FLUORESCENCE in situ hybridization , *GENETIC mutation , *TELOMERES , *DISEASE progression - Abstract
Context.--Pancreatic neuroendocrine neoplasms (Pan- NENs) represent a heterogeneous group of epithelial tumors of the pancreas showing neuroendocrine differentiation. These neoplasms are classified into well-differentiated pancreatic neuroendocrine tumors (PanNETs), which include G1, G2, and G3 tumors, and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs), which are G3 by definition. This classification mirrors clinical, histologic, and behavioral differences and is also supported by robust molecular evidence. Objective.--To summarize and discuss the state of the art regarding neoplastic progression of PanNENs. A better comprehension of the mechanisms underpinning neoplas- tic evolution and progression of these neoplasms may open new horizons for expanding biologic knowledge and ultimately for addressing new therapeutic strategies for patients with PanNENs. Data Sources.--Literature review of published studies and the authors' own work. Conclusions.--PanNETs can be seen as a unique category, where G1-G2 tumors may progress to G3 tumors mainly driven by DAXX/ATRX mutations and alternative lengthening of telomeres. Conversely, PanNECs display totally different histomolecular features more closely related to pancreatic ductal adenocarcinoma, including TP53 and Rb alterations. They seem to derive from a nonneuroendocrine cell of origin. Even the study of PanNEN precursor lesions corroborates the rationale of considering PanNETs and PanNECs as separate and distinct entities. Improving the knowledge regarding this dichotomous distinction, which guides tumor evolution and progression, will represent a critical basis for PanNEN precision oncology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.
- Author
-
Van Bockstal, Mieke R., Wesseling, Jelle, Lips, Ester H., Smidt, Marjolein, Galant, Christine, and van Deurzen, Carolien H. M.
- Subjects
CARCINOMA in situ ,DUCTAL carcinoma ,PROTEIN overexpression ,HER2 protein ,HER2 gene ,RADIOTHERAPY ,LUMPECTOMY - Abstract
In many countries, hormone receptor status assessment of ductal carcinoma in situ (DCIS) is routinely performed, as hormone receptor-positive DCIS patients are eligible for adjuvant anti-hormonal treatment, aiming to reduce the ipsilateral and contralateral breast cancer risk. Although HER2 gene amplification and its associated HER2 protein overexpression constitute a major prognostic and predictive marker in invasive breast carcinoma, its use in the diagnosis and treatment of DCIS is less straightforward. HER2 immunohistochemistry is not routinely performed yet, as the role of HER2-positivity in DCIS biology is unclear. Nonetheless, recent data challenge this practice. Here, we discuss the value of routine HER2 assessment for DCIS. HER2-positivity correlates strongly with DCIS grade: around four in five HER2-positive DCIS show high grade atypia. As morphological DCIS grading is prone to interobserver variability, HER2 immunohistochemistry could render grading more robust. Several studies showed an association between HER2-positive DCIS and ipsilateral recurrence risk, albeit currently unclear whether this is for overall, in situ or invasive recurrence. HER2-positive DCIS tends to be larger, with a higher risk of involved surgical margins. HER2-positive DCIS patients benefit more from adjuvant radiotherapy: it substantially decreases the local recurrence risk after lumpectomy, without impact on overall survival. HER2-positivity in pure biopsy-diagnosed DCIS is associated with increased upstaging to invasive carcinoma after surgery. HER2 immunohistochemistry on preoperative biopsies might therefore provide useful information to surgeons, favoring wider excisions. The time seems right to consider DCIS subtype-dependent treatment, comprising appropriate local treatment for HER2-positive DCIS patients and de-escalation for hormone receptor-positive, HER2-negative DCIS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Application of a Data Quality Framework to Ductal Carcinoma In Situ Using Electronic Health Record Data From the All of Us Research Program.
- Author
-
Berman, Lew, Ostchega, Yechiam, Giannini, John, Anandan, Lakshmi Priya, Clark, Emily, Spotnitz, Matthew, Sulieman, Lina, Volynski, Michael, and Ramirez, Andrea
- Subjects
- *
HEALTH Insurance Portability & Accountability Act , *ELECTRONIC health records , *CARCINOMA in situ , *DUCTAL carcinoma , *DATA quality - Abstract
PURPOSE: The specific aims of this paper are to (1) develop and operationalize an electronic health record (EHR) data quality framework, (2) apply the dimensions of the framework to the phenotype and treatment pathways of ductal carcinoma in situ (DCIS) using All of Us Research Program data, and (3) propose and apply a checklist to evaluate the application of the framework. METHODS: We developed a framework of five data quality dimensions (DQD; completeness, concordance, conformance, plausibility, and temporality). Participants signed a consent and Health Insurance Portability and Accountability Act authorization to share EHR data and responded to demographic questions in the Basics questionnaire. We evaluated the internal characteristics of the data and compared data with external benchmarks with descriptive and inferential statistics. We developed a DQD checklist to evaluate concept selection, internal verification, and external validity for each DQD. The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) concept ID codes for DCIS were used to select a cohort of 2,209 females 18 years and older. RESULTS: Using the proposed DQD checklist criteria, (1) concepts were selected and internally verified for conformance; (2) concepts were selected and internally verified for completeness; (3) concepts were selected, internally verified, and externally validated for concordance; (4) concepts were selected, internally verified, and externally validated for plausibility; and (5) concepts were selected, internally verified, and externally validated for temporality. CONCLUSION: This assessment and evaluation provided insights into data quality for the DCIS phenotype using EHR data from the All of Us Research Program. The review demonstrates that salient clinical measures can be selected, applied, and operationalized within a conceptual framework and evaluated for fitness for use by applying a proposed checklist. A Data Quality Framework Applied to ductal carcinoma in situ EHR data. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Surgical and irradiated case of early breast cancer in a patient with Ehlers–Danlos syndrome.
- Author
-
Yamazaki, Asumi, Tada, Hiroshi, Muroyama, Yuki, Yamazaki, Yuto, Miyashita, Minoru, Harada-Shoji, Narumi, Hamanaka, Yohei, Ebata, Akiko, Sato, Miku, Motonari, Tokiwa, Yanagaki, Mika, Kon, Tomomi, Sakamoto, Aru, Suzuki, Takashi, and Ishida, Takanori
- Subjects
EHLERS-Danlos syndrome ,JOINT hypermobility ,CONNECTIVE tissue diseases ,BREAST cancer ,BREAST biopsy ,DUCTAL carcinoma ,SENTINEL lymph node biopsy ,LUMPECTOMY - Abstract
Background: Ehlers–Danlos syndrome (EDS) is a rare inherited connective tissue disease characterized by hyperextensibility of the skin and joints and tissue fragility of the skin and blood vessels, Vascular EDS is the most severe form of EDS, with abnormal arterial fragility. There have been no reports of breast cancer occurring in patients with vascular EDS. Here, we report here a very rare case of breast cancer in a patient with vascular EDS. Case presentation: A 46-year-old woman with vascular EDS underwent partial left mastectomy and sentinel lymph node biopsy for left breast cancer (cStage 0) detected by medical examination. The final pathological diagnosis was invasive ductal carcinoma of the breast (pStage IA) [hormone receptor-positive, HER2 score 2 equivocal (FISH-positive), Ki-67LI 18%, luminal-HER2 type]. BluePrint was submitted as an aid in determining the postoperative treatment strategy, BluePrint Molecular Subtype HER2-type. However, the 10-year breast cancer mortality risk using Predict was low (5%). After consultation with the patient, the decision was made to administer postoperative radiation to the preserved breast along with hormone therapy only. There was no delay in postoperative wound healing, and the patient was free of metastatic recurrence for 9 months after surgery. Conclusion: We performed surgery, postoperative radiotherapy, and hormonal therapy in a breast cancer patient with vascular EDS without major complications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Cancer-specific alterations in nuclear matrix proteins determined by multi-omics analyses of ductal carcinoma in situ.
- Author
-
Almutairy, Ali F., Alhamed, Abdullah S., Grant, Stephen G., Falso, Miranda J., Day, Billy W., Simmons, Colton R., and Latimer, Jean J.
- Subjects
RNA sequencing ,PROTEIN expression ,GENE expression ,AMERICAN women ,DUCTAL carcinoma - Abstract
Introduction: Breast cancer (BC) is the most common cancer affecting women in the United States. Ductal carcinoma in situ (DCIS) is the earliest identifiable pre-invasive BC lesion. Estimates show that 14 to 50% of DCIS cases progress to invasive BC. Methods: Our objective was to identify nuclear matrix proteins (NMP) with specifically altered expression in DCIS and later stages of BC compared to non-diseased breast reduction mammoplasty and a contralateral breast explant culture using mass spectrometry and RNA sequencing to accurately identify aggressive DCIS. Results: Sixty NMPs were significantly differentially expressed between the DCIS and non-diseased breast epithelium in an isogenic contralateral pair of patient-derived extended explants. Ten of the sixty showed significant mRNA expression level differences that matched the protein expression. These 10 proteins were similarly expressed in non-diseased breast reduction cells. Three NMPs (RPL7A, RPL11, RPL31) were significantly upregulated in DCIS and all other BC stages compared to the matching contralateral breast culture and an unrelated non-diseased breast reduction culture. RNA sequencing analyses showed that these three genes were increasingly upregulated with BC progression. Finally, we identified three NMPs (AHNAK, CDC37 and DNAJB1) that were significantly downregulated in DCIS and all other BC stages compared to the isogenically matched contralateral culture and the nondiseased breast reduction culture using both proteomics and RNA sequencing techniques. Discussion: These genes should form the basis of, or contribute to, a molecular diagnostic panel that could identify DCIS lesions likely to be indolent and therefore not requiring aggressive treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Neutrophil-to-Lymphocyte Ratio and Prognostic Nutritional Index Are Predictors for Overall Survival after Primary Pancreatic Resection of Pancreatic Ductal Adenocarcinoma: A Single Centre Evaluation.
- Author
-
Hackner, Danilo, Merkel, Susanne, Weiß, Andreas, Krautz, Christian, Weber, Georg F., Grützmann, Robert, and Brunner, Maximilian
- Subjects
- *
NEUTROPHIL lymphocyte ratio , *PREDICTION models , *ACADEMIC medical centers , *T-test (Statistics) , *STATISTICAL significance , *NUTRITIONAL assessment , *TUMOR markers , *RETROSPECTIVE studies , *MULTIVARIATE analysis , *MANN Whitney U Test , *CHI-squared test , *DESCRIPTIVE statistics , *PANCREATIC tumors , *SURGICAL complications , *PLATELET lymphocyte ratio , *KAPLAN-Meier estimator , *DUCTAL carcinoma , *PANCREATECTOMY , *MEDICAL records , *ACQUISITION of data , *STATISTICS , *MATHEMATICAL models , *ALBUMINS , *THEORY , *DATA analysis software , *OVERALL survival , *C-reactive protein , *PROPORTIONAL hazards models - Abstract
Simple Summary: Inflammation-based prognostic markers have been recognized as useful in a range of oncologic conditions. Given the high mortality rate associated with pancreatic ductal adenocarcinoma (PDAC), the demand for accurate prognostic tools is significant. Nonetheless, the literature still shows conflicting results regarding the effectiveness of the various available scoring systems. Our data confirm that NLR and PNI are useful biomarkers regarding overall survival in PDAC. Especially in advanced disease stages, they seem to be of considerable benefit as easily accessible tools for prognosis prediction. Purpose: Prognostic inflammation-based parameters have been reported as useful tools in various oncologic diseases. Pancreatic ductal adenocarcinoma (PDAC) is characterized by a high mortality rate, making reliable prognostic markers highly desirable. However, there is still inconsistency in the literature regarding the efficacy of the different available scores. Methods: A total of 207 patients, who underwent primary resection of PDAC from January 2000 to December 2018 at the University Hospital of Erlangen, were included in this retrospective single-center study. Different biomarkers, including the preoperative neutrophil–lymphocyte ratio (NLR), the platelet–lymphocyte ratio (PLR), the c-reactive protein (CRP)–albumin ratio (CAR), the lymphocyte–CRP ratio (LCR), the prognostic nutritional index (PNI) and the modified Glasgow prognostic score (mGPS) were analyzed for their ability to predict overall survival (OS). Results: In our cohort, the median overall survival was 20.7 months. Among the investigated biomarkers, NLR and PNI were identified as independent prognostic markers (Hazard Ratio (HR) 1.6 (1.0–2.5), p = 0.048 and HR 0.6 (0.4–0.9), p = 0.018), whereas PLR, CAR, LCR and mGPS did not reach significance in the multivariate analysis. Subgroup analysis revealed that the prognostic value of NLR and PNI is particularly evident in locally advanced tumor stages (pT3/4 and pN+). Conclusions: The NLR and PNI could serve as valuable tools for estimating prognosis in patients with PDAC undergoing pancreatic resection in curative intention, especially in locally advanced tumor stages. However, conflicting results in the current literature highlight the need for further prospective studies to validate these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment.
- Author
-
Vitorakis, Nikolaos, Gargalionis, Antonios N., Papavassiliou, Kostas A., Adamopoulos, Christos, and Papavassiliou, Athanasios G.
- Subjects
- *
ADENOCARCINOMA , *CANCER , *MACROPHAGES , *CELL physiology , *IMMUNOTHERAPY , *NEUTROPHILS , *DRUG delivery systems , *IMMUNE system , *MYELOID-derived suppressor cells , *PANCREATIC tumors , *CANCER chemotherapy , *FIBROBLASTS , *DUCTAL carcinoma , *ACCURACY , *GENETIC mutation , *INDIVIDUALIZED medicine , *DRUG resistance , *REGULATORY T cells - Abstract
Simple Summary: Pancreatic cancer is one of the most lethal forms of malignancies; therefore, new treatment strategies are required to increase the patients' survival. It has been established that different cell types that surround pancreatic cancer cells, thus forming the tumor microenvironment, are responsible for tumorigenicity and inefficacy of treatments, including immunotherapy. In the present review, we aim to summarize current knowledge regarding the molecular mechanisms underpinning the interaction of cancer cells with cells of their microenvironment and discuss associated strategies to improve treatment results. Pancreatic cancer demonstrates an ever-increasing incidence over the last years and represents one of the top causes of cancer-associated mortality. Cells of the tumor microenvironment (TME) interact with cancer cells in pancreatic ductal adenocarcinoma (PDAC) tumors to preserve cancer cells' metabolism, inhibit drug delivery, enhance immune suppression mechanisms and finally develop resistance to chemotherapy and immunotherapy. New strategies target TME genetic alterations and specific pathways in cell populations of the TME. Complex molecular interactions develop between PDAC cells and TME cell populations including cancer-associated fibroblasts, myeloid-derived suppressor cells, pancreatic stellate cells, tumor-associated macrophages, tumor-associated neutrophils, and regulatory T cells. In the present review, we aim to fully explore the molecular landscape of the pancreatic cancer TME cell populations and discuss current TME targeting strategies to provide thoughts for further research and preclinical testing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Advancing Pancreatic Cancer Surgical Treatments and Proposal of New Approaches.
- Author
-
Cortiana, Viviana, Vallabhaneni, Harshitha, Gambill, Jade, Nadar, Soumiya, Itodo, Kennedy, Park, Chandler H., and Leyfman, Yan
- Subjects
- *
PATIENT selection , *MEDICAL technology , *SURVIVAL rate , *BLOOD vessels , *PANCREATIC tumors , *COMBINED modality therapy , *DUCTAL carcinoma , *QUALITY of life , *TUMOR classification - Abstract
Simple Summary: Pancreatic cancer is a significant challenge due to its aggressive nature, complex management, high mortality rate, and low 5-year survival rate. Approximately 85% of cases are adenocarcinomas, while endocrine tumors comprise less than 5%. Borderline reresections andcally advanced pancreatic cancers are difficult to treat due to frequent vascular involvement, complicating complete resections, and increasing morbidity. Various therapeutic modalities aim to improve patient outcomes. Traditionally, upfront surgery was the standard for resectable tumors, with multimodal chemotherapy being central to treatment. Understanding surgical anatomy is pivotal for enhancing outcomes. Classification systems like the MD Anderson Criteria assess tumor involvement with major blood vessels. Neoadjuvant therapy addresses micro-metastatic disease early, increasing R0 resection chances. Dr. Sanjay S. Reddy's insights highlight the importance of a multidisciplinary approach to advancing therapy and improving prognosis. Pancreatic cancer is a significant challenge in oncology due to its aggressive nature and complex management, leading to high mortality rates and a dismally low 5-year survival rate. Approximately 85% of cases manifest as adenocarcinoma, while endocrine tumors constitute less than 5%. Borderline resectable and locally advanced pancreatic cancers are particularly difficult to treat due to vascular involvement, which complicates complete resections and increases morbidity. Various therapeutic modalities aim to overcome these challenges and improve patient outcomes. Traditionally, upfront surgery was the standard for resectable tumors, with multimodal chemotherapy being central to treatment. Understanding surgical anatomy is pivotal in enhancing surgical outcomes and patient survival. Resectability challenges are several when seeking to achieve R0 resections, particularly for borderline resectable tumors. Various classification systems—the MD Anderson criteria, the NCCN criteria, the AHPA/SSAT/SSO consensus statement, and the Alliance definition—assess tumor involvement with major blood vessels, with the first of these systems being broadly accepted. Vascular staging integration is also important, with the Ishikawa staging system using preoperative imaging to assess venous involvement. Furthermore, neoadjuvant therapy enhances treatment effectiveness by addressing micro-metastatic disease early, increasing R0 resection chances, and downstaging tumors for optimal surgery. Insights from the Fox Chase Cancer Center's neoadjuvant treatment approach highlight the importance of a multidisciplinary strategy when advancing therapy and improving patient prognosis. This commentary, inspired by Dr. Sanjay S. Reddy's Keynote Conference during MedNews week, highlights current advancements and ongoing challenges in the treatment of pancreatic cancer, emphasizing the need for a comprehensive, multidisciplinary approach to improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Challenge in the cytological interpretation of a not-so-typical breast carcinoma.
- Author
-
Muniraj, Femela, Srinivasan, Sudha, and Raghavan, Vijayashree
- Subjects
- *
BREAST tumor diagnosis , *BREAST cancer diagnosis , *CANCER invasiveness , *ULCERS , *BREAST tumors , *EDEMA , *IMMUNOHISTOCHEMISTRY , *CELL lines , *DUCTAL carcinoma , *NEEDLE biopsy , *BREAST - Published
- 2024
- Full Text
- View/download PDF
18. The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma.
- Author
-
Moragas, Núria, Fernandez-Nogueira, Patricia, Recalde-Percaz, Leire, Inman, Jamie L., López-Plana, Anna, Bergholtz, Helga, Noguera-Castells, Aleix, del Burgo, Pedro J., Chen, Xieng, Sorlie, Therese, Gascón, Pere, Bragado, Paloma, Bissell, Mina, Carbó, Neus, and Fuster, Gemma
- Subjects
DUCTAL carcinoma ,CARCINOMA in situ ,EXTRACELLULAR matrix ,LOBULAR carcinoma ,EPITHELIAL cells ,BREAST cancer - Abstract
Background: A better understanding of ductal carcinoma in situ (DCIS) is urgently needed to identify these preinvasive lesions as distinct clinical entities. Semaphorin 3F (SEMA3F) is a soluble axonal guidance molecule, and its coreceptors Neuropilin 1 (NRP1) and NRP2 are strongly expressed in invasive epithelial BC cells. Methods: We utilized two cell line models to represent the progression from a healthy state to the mild-aggressive or ductal carcinoma in situ (DCIS) stage and, ultimately, to invasive cell lines. Additionally, we employed in vivo models and conducted analyses on patient databases to ensure the translational relevance of our results. Results: We revealed SEMA3F as a promoter of invasion during the DCIS-to-invasive ductal carcinoma transition in breast cancer (BC) through the action of NRP1 and NRP2. In epithelial cells, SEMA3F activates epithelialmesenchymal transition, whereas it promotes extracellular matrix degradation and basal membrane and myoepithelial cell layer breakdown. Conclusions: Together with our patient database data, these proof-of-concept results reveal new SEMA3F-mediated mechanisms occurring in the most common preinvasive BC lesion, DCIS, and represent potent and direct activation of its transition to invasion. Moreover, and of clinical and therapeutic relevance, the effects of SEMA3F can be blocked directly through its coreceptors, thus preventing invasion and keeping DCIS lesions in the preinvasive state. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Gut microbiota and pancreatic cancer risk, and the mediating role of immune cells and inflammatory cytokines: a Mendelian randomization study.
- Author
-
Zhiting Chen, Zhe Wang, Hejing Bao, and Shudong Ma
- Subjects
GUT microbiome ,PANCREATIC cancer ,BENIGN tumors ,NEUROENDOCRINE tumors ,DUCTAL carcinoma ,PANCREATIC tumors - Abstract
Introduction: Gut microbiota (GM) influences the occurrence and development of pancreatic cancer (PC), potentially through the involvement of inflammatory cytokines (IC) and immune cells (IM). We aimed to investigate the causal impact of the gut microbiota (GM) on pancreatic cancer (PC) and identify potential IC and IM mediators. Methods: The summary statistics data from whole-genome association studies of gut microbiota, immune cells, inflammatory cytokines, and four types of pancreatic tumors (MNP: Malignant neoplasm of pancreas; BNP: Benign neoplasm of pancreas; ADCP: Adenocarcinoma and ductal carcinoma of pancreas; NTCP: Neuroendocrine tumor and carcinoma of pancreas). Twosample univariable Mendelian randomization (UVMR), multivariable Mendelian randomization (MVMR), and mediation analysis were employed to assess the causal relationship between gut microbiota (GM) and pancreatic cancer (PC), as well as potential IC and IM mediators. Results: The two-sample UVMR analysis showed causal relationships between 20 gut microbiota species and pancreatic cancer, with pancreatic cancer affecting the abundance of 37 gut microbiota species. Mediation analysis revealed that Interleukin-6 (IL-6), "CD4 on naive CD4+ T cell" and "SSC-A on HLA DR+ Natural Killer" mediated the causal effects of gut microbiota on pancreatic cancer. Conclusion: This Mendelian randomization study demonstrates causal relationships between several specific gut microbiota and pancreatic cancer, as well as potential mediators (IC, IM). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma.
- Author
-
Cremin, Carol, Bedard, Angela C., Hong, Quan, Mung, Sze Wing, Nuk, Jennifer, Wong, Andrew, Akbar, Husain, Cheung, Eugene, Renouf, Daniel, Schaeffer, David, Sun, Sophie, and Schrader, Kasmintan A.
- Subjects
- *
PANCREATIC duct , *GENETIC counseling , *DUCTAL carcinoma , *GENETIC testing , *ONCOLOGY ,CANCER susceptibility - Abstract
PURPOSE: Approximately 5%-10% of patients with pancreatic ductal adenocarcinoma (PDAC) have an inherited basis, yet uptake of genetic testing remains low and subject to disparities. This study compared two genetic testing pathways available to patients referred to a provincial cancer center, BC Cancer: a traditional hereditary cancer clinic–initiated testing (HCT) pathway and a new oncology clinic–initiated testing (OCT) pathway. METHODS: Study subjects were patients with confirmed PDAC referred for genetic testing through the HCT or OCT pathway between June 1, 2020, and February 1, 2022. Charts were retrospectively reviewed for patient characteristics and testing outcomes. RESULTS: The study population was 397 patients (HCT, n = 279 and OCT, n = 118). OCT patients were more likely to have non-European ethnicity compared with HCT patients (41.9% v 25.6%, P =.004), to have earlier-stage disease (P =.012), and to have better Eastern Cooperative Oncology Group performance status than the HCT group (P =.001). A total of 306 patients completed testing (77%). OCT patients had higher test completion rates than HCT patients (odds ratio, 3.74 [95% CI, 1.66 to 9.62]). Median time for results was shorter in OCT than in HCT (53 days [IQR, 44-76] v 107 days [IQR, 63.8-158.3]). Pancreatic cancer susceptibility pathogenic gene variants were identified in 8.5% (26/306). CONCLUSION: The real-world observations in our study show that oncology clinic–initiated hereditary testing is more effective and faster than testing through hereditary cancer clinic referrals and reaches a more ethnically diverse population. This has important implications for publicly funded environments with limited resources for genetic counseling. Oncology clinic–initiated hereditary cancer testing improves access for patients with pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Deep residual learning with attention mechanism for breast cancer classification.
- Author
-
Toa, Chean Khim, Elsayed, Mahmoud, and Sim, Kok Swee
- Subjects
- *
TUMOR classification , *BREAST cancer , *DUCTAL carcinoma , *DEEP learning , *MEDICAL practice - Abstract
Invasive ductal carcinoma (IDC) is a common form of breast cancer that affects women. In traditional medical practice, physicians have to manually test and classify areas which are suspected to be cancerous. However, the literature strongly indicates that the manual segmentation process performed by medical practitioners is neither time efficient nor accurate, as it relies on their subjective judgment. This paper introduces a model called residual attention neural network breast cancer classification (RANN-BCC) to help medical practitioners in the cancer diagnostic process. RANN-BCC utilizes residual neural network (ResNet) as an expert-supportive method to aid medical practitioners in cancer diagnosis. The implementation of RANN-BCC can support the classification of whole slide imaging (WSI) into non-IDC and IDC without prior information about the presence of a cancerous lesion. The classification results demonstrate that the RANN-BCC model has achieved 92.45% accuracy, 0.98 recall, 0.91 precision, and 0.94 F-score which has outperformed other models such as CNN, AlexNet, Residual Neural Network 34 (ResNet34), and Feed-Forward Neural Network. The developed RANN-BCC model aims to help medical experts to classify IDC and non-IDC of breast cancer by learning the feature content of medical images. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Clinical Longevity of Preoperative Injection of Superparamagnetic Iron Oxide Nanoparticles for Delayed Sentinel Lymph Node Biopsy.
- Author
-
Muanamputu, Gael, Sparkman, Brian K., Louie, Raphael J., and McGuire, Kandace P.
- Subjects
- *
SENTINEL lymph node biopsy , *IRON oxide nanoparticles , *CARCINOMA in situ , *FERRIC oxide , *DUCTAL carcinoma - Abstract
Diagnosis of ductal carcinoma in situ (DCIS) represents about 25% of newly diagnosed breast cancers. There is debate about the benefit of sentinel lymph node biopsy (SLNB) for further staging and guidance of therapy in patients with DCIS. Current guidelines recommend SLNB for patients undergoing breast-conserving therapy (BCT) for DCIS. Utilizing superparamagnetic iron oxide (SPIO) nanoparticles as a tracer may allow for a delayed SLNB (d-SLNB), typically within a month of injection. We present our experience with a patient who due to complications from surgery could not complete her d-SLNB for 165 days. The SPIO tracer remained active in the lymph node and remained clinically useful for this five and a half month gap from time of injection. Further study is needed to determine the clinical longevity of SPIO in a lymph node. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Synchronous Breast and Colorectal Malignant Tumors—A Systematic Review.
- Author
-
Iorga, Cristian, Iorga, Cristina Raluca, Grigorescu, Alexandru, Bengulescu, Iustinian, Constantin, Traian, and Strambu, Victor
- Subjects
- *
BREAST tumors , *COLON tumors , *SURGICAL indications , *DUCTAL carcinoma , *MEDICAL screening , *BREAST - Abstract
The incidence of breast and colorectal cancers is well established in studies, but the synchronous occurrence of the two types of tumors is a rarity. In general, they are discovered during screening investigations following the diagnosis of an initial tumor. Objective: Our aim is to describe the main diagnostic and therapeutic challenges for synchronous breast and colorectal tumors. Materials and methods: We performed a systematic review of the literature for cases or case series, using established keywords (synchronous breast and colon tumor and synonyms) for the period of 1970–2023. Five reviewers independently screened the literature, extracted data, and assessed the quality of the included studies. The results were processed according to the PRISMA 2020 guidelines. Results: A total of 15 cases were included in the study, including 2 males (age 50 and 57) and 13 females (median age 60, with range from 40 to 79). In a vast majority of the cases, the diagnosis of synchronous tumor was prompted by the first tumor's workup. The first diagnosed tumor was colorectal in nine cases and a breast tumor in six cases. The most common histopathological type of breast tumor was invasive ductal carcinoma, and the colon tumors were exclusively adenocarcinomas. All cases had a surgical indication for both breast and colorectal tumor, except one case, in which the breast tumor had multiple metastasis. In four cases, the surgery was performed concomitantly (colectomy and mastectomy). In three cases, surgery was initially carried out for the breast tumor, followed by colon surgery. Oncological treatment was indicated depending on the tumor stage. Conclusions: For the treatment of synchronous tumors, the Tumor Board (T.B) decision is mandatory and must be personalized for each patient. Developing new methods of treatment and investigation may play an important role in the future for understanding synchronous tumor development, incidence, and outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Role of Oncostatin M in Exercise-Induced Breast Cancer Prevention.
- Author
-
Negrini, Kara A., Lin, Dan, Shah, Dhruvil, Wu, Hongke, Wehrung, Katherine M., Thompson, Henry J., Whitcomb, Tiffany, and Sturgeon, Kathleen M.
- Subjects
- *
BIOLOGICAL models , *IMMUNOGLOBULINS , *EXERCISE therapy , *RATS , *CARDIOPULMONARY system , *DUCTAL carcinoma , *ANIMAL experimentation , *UREA , *CYTOKINES , *EXERCISE tests , *PHYSICAL activity ,BREAST cancer chemotherapy ,BREAST tumor prevention - Abstract
Simple Summary: Exercise is well known to decrease the risk of breast cancer. The cellular processes that contribute to exercise-induced cancer prevention are less known. We conducted an exercise training study in rats given a chemical to induce breast cancer. Exercise increased the length of time to development of breast cancer in rats. However, when we gave the rats an antibody which binds to a certain cellular protein (oncostatin M), exercise-induced protection against breast cancer was not observed. These observations may be useful in future studies as the oncostatin M protein is produced by muscles. Thus, these results support a link between muscle use during exercise and breast cancer prevention. Future studies may examine oncostatin M and other proteins produced by exercising muscles for their potential role in breast cancer prevention. Moderate-to-vigorous-intensity physical activity decreases the risk of breast cancer. The muscle-derived cytokine (myokine), oncostatin M (OSM), has been shown to decrease breast cancer cell proliferation. We hypothesized that OSM is involved in physical activity-induced breast cancer prevention, and that OSM antibody (Anti-OSM) administration would mitigate the effect of physical activity in a rat model of mammary carcinoma. Female Sprague Dawley rats were injected with 50 mg/kg N-methyl-N-nitrosourea to induce mammary carcinogenesis. During the 20-week study, rats were exercise trained (EX) or remained sedentary (SED). Additional groups were treated with Anti-OSM antibody (SED + Anti-OSM and EX + Anti-OSM) to explore the impact of OSM blockade on tumor latency. Exercise training consisted of treadmill acclimation and progressive increases in session duration, speed, and grade, until reaching 30 min/day, 20 m/min at 15% incline. Experimentally naïve, age-matched, female rats also completed an acute exercise test (AET) with time course blood draws to evaluate OSM plasma concentrations. Relative tumor-free survival time was significantly longer in EX animals (1.36 ± 0.39) compared to SED animals (1.00 ± 0.17; p = 0.009), SED + Anti-OSM animals (0.90 ± 0.23; p = 0.019), and EX + Anti-OSM animals (0.93 ± 0.74; p = 0.004). There were no significant differences in relative tumor latency between SED, SED + Anti-OSM, or EX + Anti-OSM animals. Following the AET, OSM plasma levels trended higher compared to baseline OSM levels (p = 0.080). In conclusion, we observed that exercise-induced delay of mammary tumor development was mitigated through Anti-OSM administration. Thus, future studies of the OSM mechanism are required to lay the groundwork for developing novel chemo-prevention strategies in women who are unable or unwilling to exercise. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel.
- Author
-
Paredes de la Fuente, Rodrigo, Sucre, Santiago, Ponce, Cristina, Rattani, Ahmed Anwer Ali, and Peters, Mary Linton B.
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *RESEARCH funding , *GENOMICS , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DECISION making in clinical medicine , *CANCER patients , *DESCRIPTIVE statistics , *PANCREATIC tumors , *CANCER chemotherapy , *KAPLAN-Meier estimator , *GEMCITABINE , *DUCTAL carcinoma , *QUALITY of life , *GENETIC mutation , *PACLITAXEL , *SURVIVAL analysis (Biometry) , *OVERALL survival , *PROPORTIONAL hazards models , *REGRESSION analysis - Abstract
Simple Summary: This study explored how genetic changes influence treatment effectiveness and survival in patients with advanced pancreatic cancer. By examining tumors from 142 patients, researchers identified specific genetic mutations that can predict how well a patient responds to chemotherapy. Findings showed that mutations in certain genetic pathways are associated with longer survival and better treatment outcomes. This research highlights the importance of tailoring cancer treatment based on individual genetic profiles, potentially leading to more personalized and effective therapies for pancreatic cancer patients. (1) Background: Pancreatic ductal adenocarcinoma (PDAC) has low survival rates despite treatment advancements. Aim: This study aims to show how molecular profiling could possibly guide personalized treatment strategies, which may help improve survival outcomes in patients with PDAC. (2) Materials and Methods: A retrospective analysis of 142 PDAC patients from a single academic center was conducted. Patients underwent chemotherapy and next-generation sequencing for molecular profiling. Key oncogenic pathways were identified using the Reactome pathway database. Survival analysis was performed using Kaplan–Meier curves and Cox Proportional Hazards Regression. (3) Results: Patients mainly received FOLFIRINOX (n = 62) or gemcitabine nab-paclitaxel (n = 62) as initial chemotherapy. The median OS was 13.6 months. Longer median OS was noted in patients with NOTCH (15 vs. 12.3 months, p = 0.007) and KIT pathway mutations (21.3 vs. 12.12 months, p = 0.04). Combinatorial pathway analysis indicated potential synergistic effects on survival. In the PFS, PI3K pathway (6.6 vs. 5.7 months, p = 0.03) and KIT pathway (10.3 vs. 6.2 months, p = 0.03) mutations correlated with improved PFS within the gemcitabine nab-paclitaxel subgroup. (4) Conclusions: Molecular profiling could play a role in PDAC for predicting outcomes and responses to therapies like FOLFIRINOX and gemcitabine nab-paclitaxel. Integrating genomic data into clinical decision-making can benefit PDAC treatment, though further validation is needed to fully utilize precision oncology in PDAC management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients with Diabetes Mellitus and Pancreatic Adenocarcinoma.
- Author
-
Kolokotronis, Theodoros, Majchrzak-Stiller, Britta, Buchholz, Marie, Mense, Vanessa, Strotmann, Johanna, Peters, Ilka, Skrzypczyk, Lea, Liffers, Sven-Thorsten, Menkene, Louise Massia, Wagner, Mathias, Glanemann, Matthias, Betsou, Fay, Ammerlaan, Wim, Schmidt, Ronny, Schröder, Christoph, Uhl, Waldemar, Braumann, Chris, and Höhn, Philipp
- Subjects
- *
DIABETES complications , *CELL cycle proteins , *RESEARCH funding , *DATA analysis , *T-test (Statistics) , *MICRORNA , *POLYMERASE chain reaction , *TRANSGLUTAMINASES , *ENZYMES , *TUMOR markers , *CANCER patients , *PROTEIN microarrays , *DESCRIPTIVE statistics , *PANCREATIC tumors , *ANTIGENS , *GENE expression , *DUCTAL carcinoma , *PROTEOMICS , *WESTERN immunoblotting , *ONE-way analysis of variance , *STATISTICS , *COMPARATIVE studies , *DISEASE risk factors - Abstract
Simple Summary: Pancreatic ductal adenocarcinoma is a very lethal tumor entity with the late appearance of clinical signs and the absence of biomarkers for early diagnosis. Diabetes mellitus can increase the risk of pancreatic cancer, as well as the effect of treatment modalities, so patients with PDAC and DM represent a special study group. We validated miRNA1285-3p, TGM2, CDH-1, CD166, and S100A13 as potential meaningful biomarkers to characterize patients with PDAC + DM. The present study represents a pilot approach to address this question. The potential biomarkers presented in the current study could contribute to the search for biomarkers for the diagnosis of PDAC, enabling early detection of PDAC in DM patients in the future. Early detection of PDAC remains challenging due to the lack of early symptoms and the absence of reliable biomarkers. The aim of the present project was to identify miRNA and proteomics signatures discriminating PDAC patients with DM from nondiabetic PDAC patients. Proteomics analysis and miRNA array were used for protein and miRNA screening. We used Western blotting and Real-Time Quantitative Reverse Transcription polymerase chain reaction (qRT-PCR) for protein and miRNA validation. Comparisons between experimental groups with normal distributions were performed using one-way ANOVA followed by Tukey's post hoc test, and pairwise tests were performed using t-tests. p ≤ 0.05 was considered statistically significant. Protein clusters of differentiation 166 (CD166), glycoprotein CD63 (CD63), S100 calcium-binding protein A13 (S100A13), and tumor necrosis factor-β (TNF-β) were detected in the proteomics screening. The miRNA assay revealed a differential miRNA 1285 regulation. Previously described target proteins of miR-1285 cadherin-1 (CDH-1), cellular Jun (c-Jun), p53, mothers against decapentaplegic homolog 4 (Smad4), human transglutaminase 2 (TGM2) and yes-associated protein (YAP), were validated via Western blotting. miR-1285-3p was successfully validated as differentially regulated in PDAC + DM via qRT-PCR. Overall, our data suggest miRNA1285-3p, TGM2, CDH-1, CD166, and S100A13 as potential meaningful biomarker candidates to characterize patients with PDAC + DM. Data are available via ProteomeXchange with the identifier PXD053169. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Long-Term Oncologic Outcomes of Omitting Axillary Surgery in Breast Cancer Patients with Chest Wall Recurrence after Mastectomy.
- Author
-
Lim, Geok Hoon, Alcantara, Veronica Siton, Allen Jr., John Carson, Saffari, Seyed Ehsan, Tan, Veronique Kiak Mien, Tan, Kiat Tee Benita, Ngaserin, Sabrina, Tan, Su Ming, Leong, Lester Chee Hao, and Wong, Fuh Yong
- Subjects
- *
RISK assessment , *AXILLA , *CANCER relapse , *BREAST tumors , *AXILLARY lymph node dissection , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *METASTASIS , *RESEARCH , *DUCTAL carcinoma , *MASTECTOMY , *CARCINOMA in situ , *DISEASE risk factors - Abstract
Simple Summary: The management of the axilla for post-mastectomy breast cancer patients who develop a chest wall recurrence (CWR) remains to be established. This study aimed to determine if omitting axillary staging surgery for these patients resulted in an increased risk of second recurrence. A total of 194 patients with CWR, with a median follow-up of 59.5 (IQR 27.3–105) months, were analysed. There was no statistically significant difference in second recurrences between patients with or without axillary surgery during the excision of the CWR. Background: The management of the axilla in breast cancer patients with isolated chest wall recurrence (CWR) after mastectomy remains controversial. Although sentinel lymph node biopsy (SLNB) for restaging is feasible, its role is unclear. We aimed to determine if the omission of axillary restaging surgery in female patients with operable presumably isolated CWRs could result in an increased risk of second recurrences. Methods: In this retrospective multicentre study, patients who developed CWRs were reviewed. We excluded patients with suspected or concomitant regional/distant metastases, bilateral cancers and patients without CWR surgery. Patients' demographics, pathological data and subsequent recurrences were collected from a prospective database and were compared between patients with axillary lymph node dissection (ALND) and/or SLNB versus no axillary operation at CWR. Findings: A total of 194 patients with CWRs were eligible. The median age at CWR was 56.0 (IQR 47.0–67.0) years old. At recurrence, 8 (4.1%), 5 (2.6%) and 181 (93.3%) patients had ALND, SLNB and no axillary operation, respectively. Patients with no axillary surgery during CWR were associated with, at primary cancer, a lower incidence of ductal carcinoma in situ as diagnosis (p = 0.007) and older age (p = 0.022). Subsequent ipsilateral axillary (p = 0.768) and second recurrences (p = 0.061) were not statistically different between patients with and without axillary surgery at CWR on median follow-up of 59.5 (IQR 27.3–105) months. Interpretation: In patients without evidence of concomitant regional or distant metastasis at CWR diagnosis, omission of axillary restaging surgery was not associated with an increased ipsilateral axillary or second recurrences on long-term follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.
- Author
-
Olbromski, Mateusz, Mrozowska, Monika, Piotrowska, Aleksandra, Smolarz, Beata, and Romanowicz, Hanna
- Subjects
- *
CANCER cells , *REGULATORY T cells , *DUCTAL carcinoma , *MOLECULAR biology , *CANCER invasiveness - Abstract
A checkpoint protein called the V-domain Ig suppressor of T cell activation (VISTA) is important for controlling immune responses. Immune cells that interact with VISTA have molecules, or receptors, known as VISTA receptors. Immune system activity can be modified by the interaction between VISTA and its receptors. Since targeting VISTA or its receptors may be beneficial in certain conditions, VISTA has been studied in relation to immunotherapy for cancer and autoimmune illnesses. The purpose of this study was to examine the expression levels and interactions between VISTA and its receptors, VSIG3 and PSGL-1, in breast cancer tissues. IHC analysis revealed higher levels of proteins within the VISTA/VSIG3/PSGL-1 axis in cancer tissues than in the reference samples (mastopathies). VISTA was found in breast cancer cells and intratumoral immune cells, with membranous and cytoplasmic staining patterns. VISTA was also linked with pathological grade and VSIG3 and PSGL-1 levels. Furthermore, we discovered that the knockdown of one axis member boosted the expression of the other partners. This highlights the significance of VISTA/VSIG3/PSGL-1 in tumor stroma and microenvironment remodeling. Our findings indicate the importance of the VISTA/VSIG3/PSGL-1 axis in the molecular biology of cancer cells and the immune microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery.
- Author
-
Park, Eun Joo, Jang, Jong Keon, Byun, Jae Ho, Kim, Jin Hee, Lee, Seung Soo, Kim, Hyoung Jung, Yoo, Changhoon, Kim, Kyu-pyo, Hong, Seung-Mo, Seo, Dong-Wan, Hwang, Dae Wook, and Kim, Song Cheol
- Subjects
- *
PANCREATIC duct , *LOGISTIC regression analysis , *DUCTAL carcinoma , *SENSITIVITY & specificity (Statistics) , *COMPUTED tomography , *GENERALIZED estimating equations - Abstract
Objectives: The purpose of this study was to compare the different versions of the National Comprehensive Cancer Network (NCCN) guidelines for defining resectability of pancreatic ductal adenocarcinoma (PDAC) in predicting margin-negative (R0) resection, and to assess inter-reader agreement. Methods: This retrospective study included 283 patients (mean age, 65.1 years ± 9.4 [SD]; 155 men) who underwent upfront pancreatectomy for PDAC between 2017 and 2019. Two radiologists independently determined the resectability on preoperative CT according to the 2017, 2019, and 2020 NCCN guidelines. The sensitivity and specificity for R0 resection were analyzed using a multivariable logistic regression analysis with generalized estimating equations. Inter-reader agreement was assessed using kappa statistics. Results: R0 resection was accomplished in 239 patients (84.5%). The sensitivity and specificity averaged across two readers were, respectively, 76.6% and 29.5% for the 2020 guidelines, 74.1% and 32.9% for the 2019 guidelines, and 72.6% and 34.1% for the 2017 guidelines. Compared with the 2020 guidelines, both 2019 and 2017 guidelines showed significantly lower sensitivity for R0 resection (p ≤.009). Specificity was significantly higher with the 2017 guidelines (p =.043) than with the 2020 guidelines. Inter-reader agreements for determining the resectability of PDCA were strong (k ≥ 0.83) with all guidelines, being highest with the 2020 guidelines (k = 0.91). Conclusion: The 2020 NCCN guidelines showed significantly higher sensitivity for prediction of R0 resection than the 2017 and 2019 guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Epithelial‐myoepithelial carcinoma occurrence in the site of previously treated ductal carcinoma in situ of the breast: Imaging features with histopathologic correlation, a case report and review of the literature.
- Author
-
Hui, Jessica, Zhan, Xin, Bashir, Amani, Policeni, Fabiana, and Kim Hsieh, Su
- Subjects
- *
SQUAMOUS cell carcinoma , *CARCINOMA in situ , *DUCTAL carcinoma , *LITERATURE reviews , *MEDICAL literature , *PHYLLODES tumors , *LOBULAR carcinoma - Abstract
Key Clinical Message: Epithelial‐myoepithelial carcinoma of the breast is an extremely rare biphasic tumor. This report documents the first case of epithelial‐myoepithelial carcinoma presenting in the location of a previously treated ductal carcinoma in order to increase the awareness of this entity as a potential differential for recurrent breast lesions. Epithelial‐myoepithelial carcinoma of the breast is an exceedingly rare biphasic tumor, seldom documented in medical literature. This report describes the first known case of this entity at the site of a previously treated neoplasm in a 75‐year‐old female with a history of high‐grade ductal carcinoma in situ who presented with a new breast mass. Imaging demonstrated an oval shaped mass with microlobulated borders and hypoechoic echogenicity on ultrasound. Following multidisciplinary discussion, she underwent a mastectomy, revealing epithelial‐myoepithelial carcinoma with metaplastic squamous cell carcinoma. The patient began chemotherapy but discontinued due to poor tolerance and neurological complications. Generally, prognosis for epithelial‐myoepithelial carcinoma (World Health Organization Classification of Breast Tumors 2019, 8562/3) is highly variable, with limited available data suggesting that epithelial‐myoepithelial carcinoma may follow a course similar to that of breast adenocarcinomas with both hematogenous and lymphatic spread. Treatment typically involves curative excision, though the role of axillary lymph node sampling remains under discussion. This case underscores the need for vigilance in post‐treatment surveillance for breast cancer and highlights the importance of recognizing this entity in recurrent breast pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Special Types of Breast Cancer: Clinical Behavior and Radiological Appearance.
- Author
-
Conti, Marco, Morciano, Francesca, Amodeo, Silvia, Gori, Elisabetta, Romanucci, Giovanna, Belli, Paolo, Tommasini, Oscar, Fornasa, Francesca, and Rella, Rossella
- Subjects
BREAST cancer ,LOBULAR carcinoma ,DUCTAL carcinoma ,SYMPTOMS ,BREAST imaging ,BREAST - Abstract
Breast cancer is a complex disease that includes entities with different characteristics, behaviors, and responses to treatment. Breast cancers are categorized into subgroups based on histological type and grade, and these subgroups affect clinical presentation and oncological outcomes. The subgroup of "special types" encompasses all those breast cancers with insufficient features to belong to the subgroup "invasive ductal carcinoma not otherwise specified". These cancers account for around 25% of all cases, some of them having a relatively good prognosis despite high histological grade. The purpose of this paper is to review and illustrate the radiological appearance of each special type, highlighting insights and pitfalls to guide breast radiologists in their routine work. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.
- Author
-
Shah, Osama Shiraz, Nasrazadani, Azadeh, Foldi, Julia, Atkinson, Jennifer M., Kleer, Celina G., McAuliffe, Priscilla F., Johnston, Tyler J., Stallaert, Wayne, da Silva, Edaise M., Selenica, Pier, Dopeso, Higinio, Pareja, Fresia, Mandelker, Diana, Weigelt, Britta, Reis-Filho, Jorge S., Bhargava, Rohit, Lucas, Peter C., Lee, Adrian V., and Oesterreich, Steffi
- Subjects
- *
TRIPLE-negative breast cancer , *LOBULAR carcinoma , *ESTROGEN receptors , *BREAST cancer , *DUCTAL carcinoma - Abstract
Mixed invasive ductal and lobular carcinoma (MDLC) is a rare histologic subtype of breast cancer displaying both E-cadherin positive ductal and E-cadherin negative lobular morphologies within the same tumor, posing challenges with regard to anticipated clinical management. It remains unclear whether these distinct morphologies also have distinct biology and risk of recurrence. Our spatially resolved transcriptomic, genomic, and single-cell profiling revealed clinically significant differences between ductal and lobular tumor regions including distinct intrinsic subtype heterogeneity - e.g., MDLC with triple-negative breast cancer (TNBC) or basal ductal and estrogen receptor positive (ER+) luminal lobular regions, distinct enrichment of cell cycle arrest/senescence and oncogenic (ER and MYC) signatures, genetic and epigenetic CDH1 inactivation in lobular but not ductal regions, and single-cell ductal and lobular subpopulations with unique oncogenic signatures further highlighting intraregional heterogeneity. Altogether, we demonstrated that the intratumoral morphological/histological heterogeneity within MDLC is underpinned by intrinsic subtype and oncogenic heterogeneity which may result in prognostic uncertainty and therapeutic dilemma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Radiomics analysis combining gray-scale ultrasound and mammography for differentiating breast adenosis from invasive ductal carcinoma.
- Author
-
Wen Li, Ying Song, Xusheng Qian, Le Zhou, Huihui Zhu, Long Shen, Yakang Dai, Fenglin Dong, and Yonggang Li
- Subjects
LOBULAR carcinoma ,DUCTAL carcinoma ,RADIOMICS ,MAMMOGRAMS ,FEATURE extraction ,RECEIVER operating characteristic curves - Abstract
Objectives: To explore the utility of gray-scale ultrasound (GSUS) and mammography (MG) for radiomic analysis in distinguishing between breast adenosis and invasive ductal carcinoma (IDC). Methods: Data from 147 female patients with pathologically confirmed breast lesions (breast adenosis: 61 patients; IDC: 86 patients) between January 2018 and December 2022 were retrospectively collected. A training cohort of 113 patients (breast adenosis: 50 patients; IDC: 63 patients) diagnosed from January 2018 to December 2021 and a time-independent test cohort of 34 patients (breast adenosis: 11 patients; IDC: 23 patients) diagnosed from January 2022 to December 2022 were included. Radiomic features of lesions were extracted from MG and GSUS images. The least absolute shrinkage and selection operator (LASSO) regression was applied to select the most discriminant features, followed by logistic regression (LR) to construct clinical and radiomic models, as well as a combined model merging radiomic and clinical features. Model performance was assessed using receiver operating characteristic (ROC) analysis. Results: In the training cohort, the area under the curve (AUC) for radiomic models based on MG features, GSUS features, and their combination were 0.974, 0.936, and 0.991, respectively. In the test cohort, the AUCs were 0.885, 0.876, and 0.949, respectively. The combined model, incorporating clinical and all radiomic features, and the MG plus GSUS radiomics model were found to exhibit significantly higher AUCs than the clinical model in both the training cohort and test cohort (p<0.05). No significant differences were observed between the combined model and the MG plus GSUS radiomics model in the training cohort and test cohort (p>0.05). Conclusion: The effectiveness of radiomic features derived from GSUS and MG in distinguishing between breast adenosis and IDC is demonstrated. Superior discriminatory efficacy is shown by the combined model, integrating both modalities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Association of residual ductal carcinoma in situ with breast cancer treatment outcomes after neoadjuvant chemotherapy according to hormone receptor status.
- Author
-
Shin, Eunju, Yoo, Tae-Kyung, Kim, Jisun, Chung, Il Yong, Ko, Beom Seok, Kim, Hee Jeong, Lee, Jong Won, Son, Byung Ho, and Lee, Sae Byul
- Subjects
HORMONE receptors ,CARCINOMA in situ ,DUCTAL carcinoma ,NEOADJUVANT chemotherapy ,BREAST cancer - Abstract
Purpose: This research aimed to clarify the impact of residual ductal carcinoma in situ(DCIS) in surgical specimens obtained after neoadjuvant chemotherapy(NAC) for breast cancer on the associated prognosis outcomes. Methods: This retrospective study was performed on a cohort of 1,009 patients who achieved pCR following NAC for breast cancer and underwent subsequent breast surgery at a single institution between January 2008 and December 2019. Overall survival, local recurrence-free survival, distant metastasis-free survival, and disease-free survival of the residual and non-residual DCIS groups were the outcomes compared, with further subgroup analysis performed according to hormone receptor status. Results: 260 individuals (25.8%) presented with residual DCIS. Based on a median follow-up of 54.0 months, no significant differences in outcomes were observed between the two groups. Patients with residual DCIS and hormone receptor-negative (HR-) breast cancer demonstrated a significant decrease in distant metastasis-free survival (p = 0.030) compared to those without residual DCIS. In the HR + cohort, no significant difference was observed between the two groups. Multivariate analysis of the HR- cohort demonstrated a significant association between residual DCIS and an elevated risk for distant recurrence (hazard ratio = 2.3, 95% confidence interval = 1.01–5.20, p = 0.047). Conclusions: Residual DCIS following NAC may impact breast cancer outcomes, particularly with respect to the occurrence of distant metastasis in HR- patients. Therefore, clinicians must vigilantly monitor patients with residual DCIS after NAC, and further research is needed to expand our understanding of the clinical implications of residual DCIS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine.
- Author
-
Buchholz, Marie, Majchrzak-Stiller, Britta, Peters, Ilka, Hahn, Stephan, Skrzypczyk, Lea, Beule, Lena, Uhl, Waldemar, Braumann, Chris, Strotmann, Johanna, and Höhn, Philipp
- Subjects
- *
ADENOCARCINOMA , *BIOLOGICAL models , *IN vitro studies , *RESEARCH funding , *ANTINEOPLASTIC agents , *TREATMENT effectiveness , *IN vivo studies , *DESCRIPTIVE statistics , *CANCER patients , *PANCREATIC tumors , *MICE , *CELL lines , *DUCTAL carcinoma , *GEMCITABINE , *ANIMAL experimentation , *MOLECULAR structure , *COMPARATIVE studies , *PHARMACODYNAMICS - Abstract
Simple Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer type with rising incidences worldwide and poor survival. GP-2250 is an emerging agent showing a high antineoplastic capacity. Currently, GP-2250 is under phase I clinical trial for PDAC. This study was the first to evaluate the antineoplastic effects of GP-2250 on pancreatic adenocarcinoma in combination with Gemcitabine in a PDAC patient-derived mouse xenograft (PDX) setting. This combination showed highly synergistic effects in a primary cell culture model, as well as in a first-line and a maintenance setting using PDX. Changes in the CD133 content of treated spheroid cultures provide first indicators for this synergism. These findings demonstrate the vast potential of this highly promising combination in the maintenance therapy of PDAC patients. The novel Oxathiazinane derivative GP-2250 (Misetionamide) displays antineoplastic activity in vitro and in vivo, as previously shown in pancreatic cancer cells and in patient-derived mouse xenografts (PDX). Currently, GP 2250 is under phase I clinical trial in pancreatic ductal adenocarcinoma (PDAC). GP-2250 in combination with Gemcitabine displays a high synergistic capacity in various primary and established pancreatic cancer cell lines. Additionally, in the eight PDX models tested, the drug combination was superior in reducing tumor volume with an aggregate tumor regression (ATR) of 74% compared to Gemcitabine alone (ATR: 10%). Similarly, in a PDX maintenance setting following two weeks of treatment with nab-Paclitaxel plus Gemcitabine, the combination of GP-2250 plus Gemcitabine resulted in outstanding tumor control (ATR: 79%) compared to treatment with Gemcitabine alone (ATR: 60%). Furthermore, GP-2250 reduced the ratio of tumor-initiating CD133+ markers on the surface of PDAC cells in spheroid cultures, indicating a possible mechanism for the synergistic effect of both substances. Considering the high tolerability of GP 2250, these results may open up a new approach to maintenance therapy with GP-2250/Gemcitabine combination following nab-Paclitaxel plus Gemcitabine as first-line treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Cutaneous Metastasis in Breast Cancer: A Case Report.
- Author
-
Jamjoum, Ghader, Arab, Fatima S., Tayeb, Rama, Samkari, Ali, Johari, Adel Ali, Ashkar, Laila, and Akbar, Jumana
- Subjects
- *
METASTATIC breast cancer , *CANCER relapse , *CANCER patients , *DUCTAL carcinoma , *BREAST cancer , *CAUSES of death - Abstract
Objective: Unusual clinical course. Background: Breast cancer (BC) is the most common malignant disease in females and one of the leading causes of death worldwide. Its treatment plan includes a long-term follow-up and close surveillance, as recurrence is a wellacknowledged concern. BC can recur either locally or as a metastasis, and skin metastasis is a common complication in advanced breast cancer patients. It can present as a skin nodule, plaque, or erythematous lesion, and can be difficult to distinguish from benign skin conditions. The risk of skin metastasis is higher in patients with inflammatory BC. Treatment of such a complex condition is even more challenging, with poor prognosis. Here, we report a case of a 42-year-old woman with stage 4 luminal A BC who had soft tissue recurrence. Case Report: A 42-year-old woman with a history of left-sided BC diagnosed and treated 10 years ago presented with multiple soft tissue masses mimicking abscesses at the right lower middle of the back, bilateral thighs, and back of the neck, in the last 6 months, the largest measuring 8×10 cm. The masses were found to be metastatic BC that had spread to the skin and lungs. Because it was invasive ductal carcinoma with positive ER and PR receptors, she was started on hormonal treatment and chemotherapy. Conclusions: This case report highlights the importance of follow-up in patients with a history of BC, as the cancer can recur and spread many years after treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Low progesterone receptor levels in high-grade DCIS correlate with HER2 upregulation and the presence of invasive components.
- Author
-
Schandiz, Hossein, Farkas, Lorant, Daehoon Park, Yan Liu, Andersen, Solveig N., Geisler, Jürgen, and Sauer, Torill
- Subjects
PROGESTERONE receptors ,CARCINOMA in situ ,IN situ hybridization ,DUCTAL carcinoma ,ESTROGEN receptors - Abstract
Objective: In this study, we investigated pivotal molecular markers in human high-grade breast ductal carcinoma in situ (DCIS). Expression status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2) was measured among various subtypes (Luminal (Lum) A, LumB HER2-, LumB HER2+, HER2-enriched and triple-negative). Methods: In total, 357 DCIS cases were classified into respective subtypes, according to the 2013 St. Gallen guidelines. Each subtype was categorized into three subcategories: "Pure" (those without an invasive component), "W/invasive" (those with an invasive component), and "All" (the entire group of the given subtype). ER and PR expression were registered as intervals. Equivocal HER2 immunohistochemistry (IHC) cases (2+) were further investigated using dualcolor in situ hybridization. Results: The majority of patients (71%) were over the age of 50. We discovered no significant differences in the proportion of age between the "Pure" and "W/invasive" groups. There was no significant difference in ER/PR expression between "Pure" luminal subtypes of DCIS and "W/invasive" cases. We compared the HER2 IHC scores of "0", "1+", and "2+" among LumA and LumB HER2 subtypes and identified no statistically significant differences between "Pure" and "W/invasive" (p = 0.603). ER and PR expression = 50% cutoff value was present in > 90% of all LumA cases. The incidences of cases with ER expression at cutoff values of < 10% and = 50% in LumA were significantly different compared to other luminal subtypes (p < 0.0001). The proportion of cases with PR expression < 20% showed significant differences in the various luminal subtypes. In luminal B subtypes, low PR expression (< 20%) was significantly associated with both strong HER2 expression (3+) and the presence of an invasive component (p = 0.0001 and p = 0.0365, respectively). Conclusions: ER and PR expression at = 50% cutoff values were found in more than 90% of LumA cases. Samples with ER < 10% and = 50% in LumA were significantly different compared to other luminal subtypes (p < 0.0001). Low PR expression in high-grade DCIS was strongly associated with HER2 overexpression (3+) and an invasive component (p = 0.0001 and p = 0.0365, respectively). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Stromal lymphocytes are associated with upgrade of B3 breast lesions.
- Author
-
Kader, Tanjina, Provenzano, Elena, Jayawardana, Madawa W., Hendry, Shona, Pang, Jia-Min, Elder, Kenneth, Byrne, David J., Tjoeka, Lauren, Frazer, Helen ML., House, Eloise, Jayasinghe, Sureshni I., Keane, Holly, Murugasu, Anand, Rajan, Neeha, Miligy, Islam M., Toss, Michael, Green, Andrew R., Rakha, Emad A., Fox, Stephen B., and Mann, G. Bruce
- Subjects
LYMPHOCYTES ,SURGICAL excision ,DUCTAL carcinoma ,TUMOR microenvironment ,TUMOR-infiltrating immune cells ,UNNECESSARY surgery ,CARCINOMA in situ ,LYMPHOCYTE count - Abstract
Various histopathological, clinical and imaging parameters have been evaluated to identify a subset of women diagnosed with lesions with uncertain malignant potential (B3 or BIRADS 3/4A lesions) who could safely be observed rather than being treated with surgical excision, with little impact on clinical practice. The primary reason for surgery is to rule out an upgrade to either ductal carcinoma in situ or invasive breast cancer, which occurs in up to 30% of patients. We hypothesised that the stromal immune microenvironment could indicate the presence of carcinoma associated with a ductal B3 lesion and that this could be detected in biopsies by counting lymphocytes as a predictive biomarker for upgrade. A higher number of lymphocytes in the surrounding specialised stroma was observed in upgraded ductal and papillary B3 lesions than non-upgraded (p < 0.01, negative binomial model, n = 307). We developed a model using lymphocytes combined with age and the type of lesion, which was predictive of upgrade with an area under the curve of 0.82 [95% confidence interval 0.77–0.87]. The model can identify some patients at risk of upgrade with high sensitivity, but with limited specificity. Assessing the tumour microenvironment including stromal lymphocytes may contribute to reducing unnecessary surgeries in the clinic, but additional predictive features are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Evaluating the efficacy of laparoscopic radical antegrade modular pancreatosplenectomy in selected early-stage left-sided pancreatic cancer: a propensity score matching study.
- Author
-
Li, Zheng, Xu, Wenyan, Wang, Ting, Li, Borui, Chen, Chen, Shi, Yihua, Zhou, Chenjie, Zhuo, Qifeng, Ji, Shunrong, Liu, Wensheng, Yu, Xianjun, and Xu, Xiaowu
- Subjects
- *
ADENOCARCINOMA , *PREOPERATIVE period , *STATISTICAL models , *CANCER relapse , *T-test (Statistics) , *PATIENT safety , *RESEARCH funding , *LAPAROSCOPIC surgery , *COMPUTED tomography , *LOGISTIC regression analysis , *FISHER exact test , *TREATMENT effectiveness , *CANCER patients , *MAGNETIC resonance imaging , *SURGICAL blood loss , *TREATMENT duration , *DESCRIPTIVE statistics , *CHI-squared test , *MANN Whitney U Test , *PANCREATIC tumors , *SURGICAL complications , *KAPLAN-Meier estimator , *DUCTAL carcinoma , *PANCREATECTOMY , *SPLENECTOMY , *TUMOR classification , *COMPARATIVE studies , *PROGRESSION-free survival , *DATA analysis software , *PERIOPERATIVE care - Abstract
Background: Laparoscopic radical pancreatectomy is safe and beneficial for recectable pancreatic cancer, but the extent of resection for early-stage tumors remains controversial. Methods: Consecutive patients with left-sided pancreatic cancer who underwent either laparoscopic radical antegrade modular pancreatosplenectomy (LRAMPS, n = 54) or laparoscopic distal pancreatosplecnectomy (LDP, n = 131) between October 2020 and December 2022 were reviewed. The preoperative radiological selection criteria were as follows: (1) tumor diameter ≤ 4 cm; (2) located ≥ 1 cm from the celiac trunk; (3) didn't invade the fascial layer behind the pancreas. Results: After 1:1 propensity score matching (LRAMPS, n = 54; LDP, n = 54), baseline data were well-balanced with no differences. LRAMPS resulted in longer operation time (240.5 vs. 219.0 min, P = 0.020) and higher intraoperative bleeding volume (200 vs. 150 mL, P = 0.001) compared to LDP. Although LRAMPS harvested more lymph nodes (16 vs. 13, P = 0.008), there were no statistically significant differences in lymph node positivity rate (35.2% vs. 33.3%), R0 pancreatic transection margin (94.4% vs. 96.3%), and retroperitoneal margin (83.3% vs. 87.0%) rate. Postoperative complications did not significantly differ between the two groups. However, LRAMPS was associated with increased drainage volume (85.0 vs. 40.0 mL, P = 0.001), longer time to recover semi-liquid diet compared to LDP (5 vs. 4 days, P < 0.001) and increased daily bowel movement frequency. Tumor recurrence pattern and recurrence-free survival were comparable between the two groups, but the adjuvant chemotherapy regimens varied, and the completion rate of the 6-month intravenous chemotherapy was lower in the LRAMPS group compared to the LDP group (51.9% vs. 75.9%, P = 0.016). Conclusions: LRAMPS did not provide oncological benefits over LDP for left-sided pancreatic cancer within the selection criteria, but it increased operation time, intraoperative bleeding, and postoperative bowel movement frequency. These factors impacted the regimen selection and completion of adjuvant chemotherapy, consequently compromising the potential benefits of LRAMPS in achieving better local control. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Prognostic Evaluation of Piezo2 Channels in Mammary Gland Carcinoma.
- Author
-
Martín-Sanz, Raquel, Rodrigues-Françoso, Aline, García-Mesa, Yolanda, García-Alonso, Francisco Javier, Gómez-Muñoz, María Asunción, Malmierca-González, Sandra, Salazar-Blázquez, Rocío, García-Suárez, Olivia, and Feito, Jorge
- Subjects
- *
BREAST cancer prognosis , *RESEARCH funding , *CELL proliferation , *FISHER exact test , *CELLULAR signal transduction , *GENE expression , *CELL lines , *TUMOR suppressor genes , *IMMUNOHISTOCHEMISTRY , *DUCTAL carcinoma , *ONCOGENES , *ION channels , *PHENOTYPES - Abstract
Simple Summary: The expression of the mechanosensory Piezo2 channel has already been described in different malignant tumors. There is discordance in the literature regarding breast carcinoma, with its expression described either as decreased or increased in neoplasms with respect to benign tissue. A retrospective cohort of 125 patients whose breasts were resected for carcinoma was chosen to determine the relationship between Piezo2 and different clinical and histological variables. A significant association was found with the Ki67 proliferation index, with a tendency for most proliferative tumors to be positive for Piezo2. In the last decade, a group of Ca2+ channels called Piezo were discovered, demonstrating a decisive role in the cellular response to mechanical stimuli and being essential in the biological behavior of cells regarding the extracellular compartment. Several investigations have suggested a potential role in carcinogenesis, with a tumor suppressor role in some cases but increased expression in several high-grade neoplasms. Regarding Piezo2 expression in mammary gland neoplasms, a protective role for Piezo2 was initially suggested, but a subsequent study demonstrated a relationship between Piezo2 expression and the highly aggressive triple-negative phenotype of breast carcinoma. A cohort of 125 patients with clinical follow-up was chosen to study Piezo2 expression and clarify its clinical implications using the same immunohistochemical evaluation performed for other breast carcinoma parameters. Fisher's exact test was chosen to identify potential relationships between the different variables. A significant association was found with the Ki67 proliferation index, but not with mitoses. The tendency of most proliferative tumors was to have an increased score for Piezo2. A similar association was found between Piezo2 expression and perineural invasion. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Improved Pancreatic Cancer Detection and Localization on CT Scans: A Computer-Aided Detection Model Utilizing Secondary Features.
- Author
-
Ramaekers, Mark, Viviers, Christiaan G. A., Hellström, Terese A. E., Ewals, Lotte J. S., Tasios, Nick, Jacobs, Igor, Nederend, Joost, Sommen, Fons van der, and Luyer, Misha D. P.
- Subjects
- *
PANCREAS radiography , *ADENOCARCINOMA , *RECEIVER operating characteristic curves , *RESEARCH funding , *COMPUTED tomography , *EARLY detection of cancer , *CANCER patients , *DIAGNOSIS , *RETROSPECTIVE studies , *HOSPITALS , *DESCRIPTIVE statistics , *DECISION making , *PANCREATIC tumors , *PANCREAS , *COMPUTER-aided diagnosis , *DEEP learning , *DUCTAL carcinoma , *MEDICAL records , *ACQUISITION of data , *DIGESTIVE organs , *ALGORITHMS , *SENSITIVITY & specificity (Statistics) - Abstract
Simple Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, and most patients present with advanced or irresectable disease due to late recognition. Radiological imaging modalities such as CT scans are key in providing information on the presence or absence of tumors. However, an assessment of pancreatic cancer requires specific radiological expertise, and small tumors are easily overlooked. Computer-aided detection (CAD) using artificial intelligence (AI) techniques is promising and may help in the early detection of pancreatic tumors. In this study, we developed a deep learning-based tumor detection framework that can detect pancreatic head cancer on CT scans with high accuracy when incorporating clinically relevant information. We demonstrate that a tumor detection framework utilizing CT scans and secondary signs of pancreatic tumors results in an increased detection accuracy for the detection of pancreatic head tumors. The early detection of pancreatic ductal adenocarcinoma (PDAC) is essential for optimal treatment of pancreatic cancer patients. We propose a tumor detection framework to improve the detection of pancreatic head tumors on CT scans. In this retrospective research study, CT images of 99 patients with pancreatic head cancer and 98 control cases from the Catharina Hospital Eindhoven were collected. A multi-stage 3D U-Net-based approach was used for PDAC detection including clinically significant secondary features such as pancreatic duct and common bile duct dilation. The developed algorithm was evaluated using a local test set comprising 59 CT scans. The model was externally validated in 28 pancreatic cancer cases of a publicly available medical decathlon dataset. The tumor detection framework achieved a sensitivity of 0.97 and a specificity of 1.00, with an area under the receiver operating curve (AUROC) of 0.99, in detecting pancreatic head cancer in the local test set. In the external test set, we obtained similar results, with a sensitivity of 1.00. The model provided the tumor location with acceptable accuracy obtaining a DICE Similarity Coefficient (DSC) of 0.37. This study shows that a tumor detection framework utilizing CT scans and secondary signs of pancreatic cancer can detect pancreatic tumors with high accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Combined PIVKA II and Vimentin-Guided EMT Tracking in Pancreatic Adenocarcinoma Combined Biomarker-Guided EMT Tracking in PDAC.
- Author
-
Farina, Antonella, Viggiani, Valentina, Cortese, Francesca, Moretti, Marta, Tartaglione, Sara, Angeloni, Antonio, and Anastasi, Emanuela
- Subjects
- *
PROTEIN analysis , *PROTEIN precursors , *ADENOCARCINOMA , *EPITHELIAL-mesenchymal transition , *RESEARCH funding , *EARLY detection of cancer , *ENZYME-linked immunosorbent assay , *CYTOSKELETAL proteins , *TUMOR markers , *VITAMIN K , *IN vivo studies , *METASTASIS , *PANCREATIC tumors , *GENE expression , *CELL lines , *DUCTAL carcinoma , *WESTERN immunoblotting , *VITAMIN deficiency , *ELECTROCHEMICAL analysis - Abstract
Simple Summary: Protein Induced by Vitamin K Absence (PIVKA II), also known as Des-γ-Carboxy prothrombin (DCP), is an established tumor marker for hepatocellular carcinoma (HCC) and a good diagnostic performance has also been demonstrated for Pancreatic Ductal Adenocarcinoma (PDAC). Circulating PIVKA II has been recently associated in vitro with epithelial-to-mesenchymal transition (EMT) activation in pancreatic origin cells PANC-1. The aim of this manuscript is to investigate whether this association is also detectable in vivo. The matter of this research lies in the fact that the diagnostic performance of PIVKA II in PDAC, along with its association with the EMT program, suggests that this molecule could be considered an indirect indicator of EMT and, therefore, a marker of the acquisition of an aggressive phenotype. "Background/Aim": the current inability to diagnose Pancreatic Cancer Adenocarcinoma (PDAC) at an early stage strongly influences therapeutic strategies. Protein Induced by Vitamin K Absence (PIVKA II) showed an accurate diagnostic performance for PDAC. Since circulating PIVKA II has been recently associated with pancreatic origin cells with Vimentin, an epithelial-to-mesenchymal transition (EMT) early activation marker, the aim of this study was to investigate in vivo the combination between the two proteins. "Materials and Methods": we assayed the presence of PIVKA II and Vimentin proteins by using different diagnostic methods. A total of 20 PDAC patients and 10 healthy donors were tested by Western Blot analysis; 74 PDAC patient and 46 healthy donors were assayed by ECLIA and Elisa. "Results": Western Blot analysis showed the concomitant expression of PIVKA II and Vimentin in PDAC patient sera. Immunometric assay performed on a larger cohort of patients demonstrated that 72% of PIVKA II-positive PDAC patients were Vimentin-positive. Additionally, in a group of PDAC patients with PIVKA II levels ≥2070 ng/mL, the percentage of Vimentin-positive subjects reached 84%. "Conclusion": the association between PIVKA II protein and the EMT suggests that this molecule could be considered a marker of the acquisition of an aggressive phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Use of Vascular Shunt at the Time of Pancreatectomy with Venous Resection: A Systematic Review.
- Author
-
Libia, Annarita, Marchese, Tiziana, D'Ugo, Stefano, Piscitelli, Prisco, Castellana, Fabio, Clodoveo, Maria Lisa, Zupo, Roberta, and Spampinato, Marcello Giuseppe
- Subjects
- *
ADENOCARCINOMA , *ISCHEMIA , *SURGICAL anastomosis , *BLOOD vessels , *SURGICAL therapeutics , *DESCRIPTIVE statistics , *VASCULAR surgery , *PANCREATIC tumors , *SYSTEMATIC reviews , *SURGICAL complications , *DISEASES , *MEDLINE , *PANCREATICODUODENECTOMY , *LONGITUDINAL method , *PANCREATECTOMY , *MEDICAL databases , *DUCTAL carcinoma , *POSTOPERATIVE period , *LIVER , *ONLINE information services , *BOWEL obstructions , *DISEASE complications - Abstract
Simple Summary: This manuscript systematically reviewed the literature on the use of vascular shunts during advanced pancreatic surgery, analyzing intraoperative and postoperative outcomes, and enlightening excellent long-term patency, negligible additional operative time, and acceptable postoperative morbidity. The importance of the study was to underline feasibility of this technical artifice, which may help expert surgeons to achieve clear margins in borderline or locally advanced PDAC. Background: The rising diffusion of vascular resections during complex pancreatectomy for malignancy, for both oncological and technical matters, brought with it the use of vascular shunts, either temporary or definitive, to prevent bowel congestion and liver ischemia. This study aimed to systematically review the literature on the technical feasibility of vascular shunts during advanced pancreatic surgery, analyzing intraoperative and postoperative outcomes. Methods: A systematic literature search was performed on PubMed, Scopus, Web of Science, and the Cochrane Library Central, according to PRISMA guidelines. Studies published before 2006 were excluded, considering the lack of a standardized definition of locally advanced pancreatic cancer. The main outcomes evaluated were the overall complication rate and shunt patency. Results: Among 789 papers retrieved from the database search, only five fulfilled the inclusion criteria and were included in the review, amounting to a total of 145 patients undergoing a shunt creation at the time of pancreatectomy. Pancreatic adenocarcinoma (PDAC) was found to be the most common diagnosis and pancreaticoduodenectomy was the main surgical procedure, accounting for 88% and 83% of the overall cohort, respectively. The distal splenorenal shunt was the most performed. Overall, 44 out of 145 patients (30%) experienced postoperative complications; the long-term patency of definitive shunts was 83% (110 out of 120 patients). Conclusions: An increasing number of patients with borderline resectable or locally advanced PDAC are becoming amenable to resection and shunt creation may facilitate vascular resection with clear margins, becoming a valid tool of modern pancreatic surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Resection Margin Status and Long-Term Outcomes after Pancreaticoduodenectomy for Ductal Adenocarcinoma: A Tertiary Referral Center Analysis.
- Author
-
Quero, Giuseppe, De Sio, Davide, Fiorillo, Claudio, Lucinato, Chiara, Panza, Edoardo, Biffoni, Beatrice, Langellotti, Lodovica, Laterza, Vito, Scaglione, Giulia, Taglioni, Flavia, Massimiani, Giuseppe, Menghi, Roberta, Rosa, Fausto, Mezza, Teresa, Alfieri, Sergio, and Tondolo, Vincenzo
- Subjects
- *
ADENOCARCINOMA , *LYMPH nodes , *TREATMENT effectiveness , *RETROSPECTIVE studies , *MULTIVARIATE analysis , *TERTIARY care , *DESCRIPTIVE statistics , *PANCREATIC tumors , *PANCREATICODUODENECTOMY , *SURGICAL margin , *ODDS ratio , *DUCTAL carcinoma , *PROGRESSION-free survival , *CANCER patient psychology , *COMPARATIVE studies , *CONFIDENCE intervals , *MEDICAL referrals , *OVERALL survival - Abstract
Simple Summary: This study investigates the impact of resection margin (R) status on overall survival (OS) and disease-free survival (DFS) in patients undergoing pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC). A retrospective analysis of 167 PD cases from 2012 to 2023 revealed that 62.8% achieved negative margins (R0), while 37.1% had positive margins (R1). Patients with R1 status had significantly lower OS (23 vs. 36 months, p = 0.003) and DFS (10 vs. 18 months, p = 0.004) compared to R0 patients. Multivariate analysis identified R1 status and positive lymph nodes (N+) as independent factors adversely affecting both OS and DFS. Specifically, among patients with N+ disease, R1 status was associated with a notably decreased DFS (10 vs. 16 months, p = 0.05). The study concludes that achieving R0 status during PD is crucial for improved long-term outcomes, emphasizing the importance of radical surgery, especially in patients with lymph node involvement. The influencing role of resection margin (R) status on long-term outcomes, namely overall (OS) and disease-free survival (DFS), after pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) is not still clear. The aim of this study is to evaluate the prognostic impact of R status after PD and to define tumor characteristics associated with a positive resection margin (R1). All PDs for PDAC performed between 2012 and 2023 were retrospectively enrolled. The effect of R status, patient clinico-demographic features, and tumor features on OS and DFS were assessed. One-hundred and sixty-seven patients who underwent PD for PDAC were included in the study. R0 was achieved in 105 cases (62.8%), while R1 was evidenced in 62 patients (37.1%). R1 was associated with a decreased OS (23 (13–38) months) as compared to R0 (36 (21–53) months) (p = 0.003). Similarly, DFS was shorter in R1 patients (10 (6–25) months) as compared to the R0 cohort (18 (9–70) months) (p = 0.004), with a consequent higher recurrence rate in cases of R1 (74.2% vs. 64.8% in the R0 group; p = 0.04). In the multivariate analysis, R1 and positive lymph nodes (N+) were the only independent influencing factors for OS (OR: 1.6; 95% CI: 1–2.5; p = 0.03 and OR: 1.7; 95% CI: 1–2.8; p = 0.04) and DFS (OR: 1.5; 95% CI: 1–2.1; p = 0.04 and OR: 1.8; 95% CI: 1.1–2.7; p = 0.009). Among 111 patients with N+ disease, R1 was associated with a significantly decreased DFS (10 (8–11) months) as compared to R0N+ patients (16 (11–21) months) (p = 0.05). In conclusion, the achievement of a negative resection margin is associated with survival benefits, particularly in cases of N1 disease. In addition, R0 was recognized as an independent prognostic feature for both OS and DFS. This further outlines the relevant role of radical surgery on long-term outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. 양측 흉벽 이소성 유방에 동시 발생한 침윤성 유방암과 섬유선종: 증례 보고 및 문헌 고찰
- Author
-
김지희
- Subjects
- *
ECTOPIC tissue , *MAGNETIC resonance mammography , *ABDOMINAL wall , *DUCTAL carcinoma , *EMBRYOLOGY - Abstract
Ectopic breast tissue, which results from incomplete regression of the mammary line during embryogenesis, is observed in 0.2%-6% of the population. Carcinoma development in ectopic breast tissue, especially in the abdominal or chest wall, is rare. Here we present the unusual case of a 38-year-old woman with invasive ductal carcinoma in the ectopic breast tissue on the left side of the chest wall and concurrent fibroadenoma in the ectopic breast tissue on the right side. We also describe the US and MR findings of these masses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. HPV Detection in Breast Tumors and Associated Risk Factors in Northeastern Brazil.
- Author
-
Nascimento, Kamylla Conceição Gomes, São Marcos, Bianca de França, Fontes, Pedro Henrique Bezerra, Isídio, Beatriz Eda de Oliveira, Leão, Stephanie Loureiro, da Silva, Gabriel Romulo Parente, Lussón, David Beltrán, dos Santos, Daffany Luana, Leal, Lígia Rosa Sales, Espinoza, Benigno Cristofer Flores, de Macêdo, Larissa Silva, de França Neto, Pedro Luiz, Silva, Anna Jéssica Duarte, Silva Neto, Jacinto Costa, Santos, Vanessa Emanuelle Pereira, and de Freitas, Antonio Carlos
- Subjects
- *
TRIPLE-negative breast cancer , *HUMAN papillomavirus , *VIRUS diseases , *DUCTAL carcinoma , *BREAST cancer , *BREAST - Abstract
Breast cancer risk factors include lifestyle, genetic–hormonal influences, and viral infections. Human papillomavirus (HPV), known primarily as the etiological agent of cervical cancer, also appears active in breast carcinogenesis, as evidenced in our study of 56 patients from northeastern Brazil. We assessed the clinical and sociodemographic characteristics, correlating them with various breast cancer tumor types. HPV detection involved amplifying the L1 region, with viral load measured using the E2/E6 ratio and viral activity indicated by E5 oncogene expression. Predominantly, patients over 56 years of age with healthy lifestyles showed a high incidence of invasive ductal carcinoma and triple-negative breast cancer. HPV was detected in 35.7% of cases, mostly HPV16, which is associated with high viral loads (80 copies per cell) and significant E5 expression. These results hint at a possible link between HPV and breast carcinogenesis, necessitating further studies to explore this association and the underlying viral mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. TP53 p.R337H Germline Variant among Women at Risk of Hereditary Breast Cancer in a Public Health System of Midwest Brazil.
- Author
-
Corrêa, Tatiana Strava, Asprino, Paula Fontes, de Oliveira, Eduarda Sabá Cordeiro, Leite, Ana Carolina Rathsam, Weis, Luiza, Achatz, Maria Isabel, de Oliveira, Claudiner Pereira, Sandoval, Renata Lazari, and Barroso-Sousa, Romualdo
- Subjects
- *
GENETIC carriers , *LI-Fraumeni syndrome , *BREAST cancer , *GENETIC testing , *DUCTAL carcinoma , *BREAST - Abstract
Despite the high prevalence of TP53 pathogenic variants (PV) carriers in the South and Southeast regions of Brazil, germline genetic testing for hereditary breast cancer (HBC) is not available in the Brazilian public health system, and the prevalence of Li-Fraumeni syndrome (LFS) is not well established in other regions of Brazil. We assessed the occurrence of TP53 p.R337H carriers among women treated for breast cancer (BC) between January 2021 and January 2022 at public hospitals of Brasilia, DF, Brazil. A total of 180 patients who met at least one of the NCCN criteria for HBC underwent germline testing; 44.4% performed out-of-pocket germline multigene panel testing, and 55.6% were tested for the p.R337H variant by allelic discrimination PCR. The median age at BC diagnosis was 43.5 years, 93% had invasive ductal carcinoma, 50% had estrogen receptor-positive/HER2 negative tumors, and 41% and 11% were diagnosed respectively at stage III and IV. Two patients (1.11%) harbored the p.R337H variant, and cascade family testing identified 20 additional carriers. The TP53 p.R337H detection rate was lower than that reported in other studies from south/southeast Brazil. Nonetheless, identifying TP53 PV carriers through genetic testing in the Brazilian public health system could guide cancer treatment and prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Baseline Characteristics and Use of Pretherapeutic 18F-Fluorodeoxyglucose-PET for Pancreatic Cancer.
- Author
-
Carlson, Danielle M., Abdelrahman, Amro M., Adjei Antwi, Stella K., Tomlinson, Jennifer L., Trivedi, Kamaxi, Karbhari, Aashna, Patnam Gopal Chetty, Nandakumar, Halfdanarson, Thor R., Goenka, Ajit H., and Truty, Mark J.
- Subjects
- *
CONTINUING education units , *ADENOCARCINOMA , *BIOPSY , *PEARSON correlation (Statistics) , *RADIOPHARMACEUTICALS , *T-test (Statistics) , *DEOXY sugars , *LOGISTIC regression analysis , *POSITRON emission tomography computed tomography , *TREATMENT effectiveness , *RETROSPECTIVE studies , *MAGNETIC resonance imaging , *POSITRON emission tomography , *DESCRIPTIVE statistics , *MANN Whitney U Test , *CHI-squared test , *PANCREATIC tumors , *LONGITUDINAL method , *ODDS ratio , *DUCTAL carcinoma , *COMBINED modality therapy , *STATISTICS , *TUMOR antigens , *CANCER patient psychology , *COMPARATIVE studies , *DATA analysis software , *CONFIDENCE intervals , *BIOMARKERS - Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy. Surgical resection is the only curative modality combined with neoadjuvant chemotherapy to improve survival. Given the limitations of traditional responses such as cross-sectional imaging (CT/MRI) or tumor markers, carbohydrate antigen 19-9 (CA19-9), the 2023 National Comprehensive Cancer Network guidelines included 18F-fluorodeoxyglucose (FDG)-PET as an adjunct to assess response to neoadjuvant chemotherapy. There are common misconceptions on the metabolic activity (tumor avidity) in PDAC so we aimed to describe the baseline characteristics and use of FDG-PET in a cohort of treatment-naive patients with PDAC. STUDY DESIGN: A single-center retrospective study was conducted capturing all biopsy-proven, treatmentnaive patients with PDAC who underwent either baseline FDG-PET/CT or FDG-PET/MRI imaging between 2008 and 2023. Baseline FDG-PET characteristics were collected, including primary tumors' maximum standardized uptake value defined as metabolic activity (FDG uptake) of tumor compared with surrounding pancreatic parenchymal background, and the identification of extrapancreatic metastatic disease. RESULTS: We identified 1,095 treatment-naive patients with PDAC who underwent baseline FDG-PET imaging at diagnosis. CA19-9 was elevated in 76% of patients. Overall, 96.3% (1,054) of patients had FDG-avid tumors with a median maximum standardized uptake value of 6.4. FDG-PET also identified suspicious extrapancreatic metastatic lesions in 50% of patients, with a higher proportion (p < 0.001) in PET/MRI (59.9%) vs PET/CT (44.3%). After controlling for CA19-9 elevation, PET/MRI was superior in detection of extrapancreatic lesions compared with PET/CT. CONCLUSIONS: FDG-PET has significant use in PDAC as a baseline imaging modality earlier neoadjuvant therapy given the majority of tumors are FDG-avid. FDG-PET can identify additional extrapancreatic suspicious lesions allowing for optimal initial staging, with PET/MRI having increased sensitivity over PET/CT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Breast cancer learning health system: Patient information from a data and analytics platform characterizes care provided.
- Author
-
Levine, Mark N., Kemppainen, Joel, Rosenberg, Morgan, Pettengell, Christopher, Bogach, Jessica, Whelan, Tim, Saha, Ashirbani, Ranisau, Jonathan, and Petch, Jeremy
- Subjects
- *
BREAST cancer , *CANCER patients , *DUCTAL carcinoma , *CLINICAL medicine , *DEATH rate - Abstract
Purpose: In a learning health system (LHS), data gathered from clinical practice informs care and scientific investigation. To demonstrate how a novel data and analytics platform can enable an LHS at a regional cancer center by characterizing the care provided to breast cancer patients. Methods: Socioeconomic information, tumor characteristics, treatments and outcomes were extracted from the platform and combined to characterize the patient population and their clinical course. Oncologists were asked to identify examples where clinical practice guidelines (CPGs) or policy changes had varying impacts on practice. These constructs were evaluated by extracting the corresponding data. Results: Breast cancer patients (5768) seen at the Juravinski Cancer Centre between January 2014 and June 2022 were included. The average age was 62.5 years. The commonest histology was invasive ductal carcinoma (74.6%); 77% were estrogen receptor‐positive and 15.5% were HER2 Neu positive. Breast‐conserving surgery (BCS) occurred in 56%. For the 4294 patients who received systemic therapy, the initial indications were adjuvant (3096), neoadjuvant (828) and palliative (370). Metastases occurred in 531 patients and 495 patients died. Lowest‐income patients had a higher mortality rate. For the adoption of CPGs, the uptake for adjuvant bisphosphonate was very low, 8% as predicted, compared to 64% for pertuzumab, a HER2 targeted agent and 40.2% for CD4/6 inhibitors in metastases. During COVID‐19, the provincial cancer agency issued a policy to shorten the duration of radiation after BCS. There was a significant reduction in the average number of fractions to the breast by five fractions. Conclusion: Our platform characterized care and the clinical course of breast cancer patients. Practice changes in response to regulatory developments and policy changes were measured. Establishing a data platform is important for an LHS. The next step is for the data to feedback and change practice, that is, close the loop. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.
- Author
-
Hutten, Stefan J, Messal, Hendrik A, Lips, Esther H, Sheinman, Michael, Ciwinska, Marta, Braams, Esmee, van der Borden, Carolien, Kristel, Petra, Stoffers, Saskia, Wessels, Lodewyk FA, Wesseling, Jelle, Jonkers, Jos, van Rheenen, Jacco, Schmidt, Marjanka, Bhattacharjee, Proteeti, Thompson, Alastair, Nik‐Zainal, Serena, Davies, Helen, Sawyer, Elinor J, and Futreal, Andrew
- Subjects
DUCTAL carcinoma ,PRECANCEROUS conditions ,CARCINOMA in situ ,BREAST cancer ,EPITHELIUM ,GENOMICS - Abstract
Mutations are abundantly present in tissues of healthy individuals, including the breast epithelium. Yet it remains unknown whether mutant cells directly induce lesion formation or first spread, leading to a field of mutant cells that is predisposed towards lesion formation. To study the clonal and spatial relationships between morphologically normal breast epithelium adjacent to pre‐cancerous lesions, we developed a three‐dimensional (3D) imaging pipeline combined with spatially resolved genomics on archival, formalin‐fixed breast tissue with the non‐obligate breast cancer precursor ductal carcinoma in situ (DCIS). Using this 3D image‐guided characterization method, we built high‐resolution spatial maps of DNA copy number aberration (CNA) profiles within the DCIS lesion and the surrounding normal mammary ducts. We show that the local heterogeneity within a DCIS lesion is limited. However, by mapping the CNA profiles back onto the 3D reconstructed ductal subtree, we find that in eight out of 16 cases the healthy epithelium adjacent to the DCIS lesions has overlapping structural variations with the CNA profile of the DCIS. Together, our study indicates that pre‐malignant breast transformations frequently develop within mutant clonal fields of morphologically normal‐looking ducts. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.